

# Design-based nested instrumental variable analysis

Zhe Chen<sup>1</sup>, Xinran Li<sup>2</sup>, Michael O. Harhay<sup>1</sup>, and Bo Zhang<sup>\*3</sup>

<sup>1</sup>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania

<sup>2</sup>Department of Statistics, University of Chicago

<sup>3</sup>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center

## Abstract

Two binary instrumental variables (IVs) are *nested* if individuals who comply under one binary IV also comply under the other. This situation often arises when the two IVs represent different intensities of encouragement or discouragement to take the treatment—one stronger than the other. In a nested IV structure, treatment effects can be identified for two latent subgroups: always-compliers and switchers. Always-compliers are individuals who comply even under the weaker IV, while switchers are those who do not comply under the weaker IV but do under the stronger one. In this article, we introduce a novel pair-of-pairs nested IV (PoP-NIV) design, where each matched stratum consists of four units organized in two pairs. Under this pair-of-pairs design, we develop design-based inferential methods for estimating the always-complier sample average treatment effect (ACO-SATE) and switcher sample average treatment effect (SW-SATE). In a nested IV analysis, IV assignment is randomized within each IV pair; however, whether a study unit receives the weaker or stronger IV may not be randomized. To address this complication, we then propose a novel *partly biased randomization scheme* and study design-based inference under this new scheme. Using extensive simulation studies, we demonstrate the validity of the proposed method and assess its power under different scenarios. Applying the nested IV framework, we estimated that 52.2% (95% CI: 50.4%–53.9%) of participants enrolled at the Henry Ford Health System in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial were always-compliers, while 26.7% (95% CI: 24.5%–28.9%) were switchers. Among always-compliers, flexible sigmoidoscopy was associated with a trend toward a decreased colorectal cancer rate (−0.62%; 95% CI: −1.90% to 0.65%). No effect was detected among switchers (1.46%; 95% CI: −1.97% to 4.91%). This offers a richer interpretation of why no increase in the intention-to-treat effect was observed after 1997, even though the compliance rate rose.

**Keywords:** Biased randomization; Design-based inference; Heterogeneous treatment effect; Principal stratification; Switcher

---

<sup>\*</sup>Assistant Professor of Biostatistics, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center. Email: [bzhang3@fredhutch.org](mailto:bzhang3@fredhutch.org).

# 1 Introduction

## 1.1 Design-based instrumental variable analysis

In many practical scenarios, the treatment and outcome of interest may be confounded by unmeasured variables. For example, in studies assessing the impact of educational attainment on future earnings, unobserved factors such as ambition and perseverance likely influence both educational attainment and earnings. These latent traits are difficult, if not impossible, to measure, posing significant challenges for valid causal inference. An instrumental variable (IV) provides a strategy to address this issue by leveraging a source of variation in the treatment that is independent of unmeasured confounders and affects the outcome only through its effect on the treatment. While direct randomization of the treatment may be infeasible in many studies, random variation in encouragement or eligibility for treatment can sometimes be exploited towards conducting valid causal inference. A classic example is provided by Angrist and Krueger (1991), who used individuals' quarter of birth as an IV to estimate the causal effect of schooling on earnings. Quarter of birth was shown to influence educational attainment—albeit modestly—and is assumed to affect earnings only through its impact on education. Crucially, unlike years of schooling, quarter of birth is essentially random.

A valid binary instrumental variable—to be formally defined later—can non-parametrically identify the treatment effect within a latent subgroup known as compliers (Angrist et al., 1996). Furthermore, under additional assumptions that limit treatment effect heterogeneity, a valid IV may enable partial or even point identification of the treatment effect in the overall population. For a comprehensive discussion of such identification assumptions, see Swanson et al. (2018). Practical strategies for identifying valid IVs are reviewed in Angrist and Krueger (2001).

In a thought-provoking piece, Imbens and Rosenbaum (2005) introduced a randomization inference-based approach to instrumental variable analysis. Unlike traditional methods grounded in structural equation modeling and moment conditions, Imbens and Rosenbaum's approach (2005) enables exact hypothesis testing for a class of sharp null hypothe-

ses. Notably, it preserves valid inference even in challenging settings where the IV is only weakly correlated with the treatment—circumstances under which conventional methods such as two-stage least squares (2SLS) are known to produce biased results (Bound et al., 1995; Imbens and Rosenbaum, 2005).

This randomization inference framework for IV analysis has since been extended in multiple directions. These include factorial designs with noncompliance (Blackwell and Pashley, 2023); binary IVs that achieve validity only after adjustment for baseline covariates via matching (Small and Rosenbaum, 2008); continuous IVs and weak null hypotheses such as the sample average treatment effect (SATE) among compliers (Baiocchi et al., 2010); cluster-randomized encouragement designs with individual-level noncompliance (Zhang et al., 2022); biased randomization schemes (Small and Rosenbaum, 2008; Fogarty et al., 2021); and approaches to bounding the SATE of the entire study cohort (Chen et al., 2025).

## **1.2 Nested IV: people respond to stronger incentives**

An important characteristic of an instrumental variable is its compliance rate, defined as the difference in the proportion of participants who receive treatment when encouraged versus when discouraged. Compliance rates can vary across studies, and an individual participant’s compliance behavior may differ depending on which encouragement is applied. Recently, Wang et al. (2024) introduced the concept of nested IVs: a binary IV is nested within another binary IV if two IVs differ in their induced compliance rates, and a complier under the weaker IV remains a complier under the stronger IV. Notably, the nested IV assumption does not impose additional restrictions on latent subgroup membership.

The classical monotonicity assumption (Angrist et al., 1996) is a statement about cross-world potential outcomes—specifically, the potential treatment received under two levels of a single binary instrumental variable. These outcomes cannot be observed simultaneously for the same individual, hence the term “cross-world.” Similarly, the nested IV assumption concerns the structure of four potential treatment-received outcomes defined by two binary IVs. Like other cross-world assumptions, it cannot be directly verified from data; however,

in many applications, researchers have reasonable grounds—often informed by economic theory or behavioral science—to believe such assumptions hold. For example, in a multi-centre clinical trial, large differences in the compliance rates across sites or time periods may support the assumption that a complier under a low-compliance-inducing IV would remain a complier under a high-compliance-inducing IV. These differences in the compliance rates are often attributable to identifiable factors; in the Prostate, Lung, Colorectal and Ovarian (PLCO) trial, for instance, the compliance rate at the Henry Ford Health System increased sharply from 50% to 90% after the site switched from a dual consent to a single consent process (Marcus et al., 2014). Nested IV structures also arise in policy research. For example, Hull (2018) and Guo et al. (2025) used twinning (bearing two children in one delivery) at the second birth as an IV for realized fertility before and after the implementation of a birth control policy. Conditional on the policy status (absence or presence of birth control), a complier is defined as a mother who would have two children if the second birth is a singleton and three children if the second birth is a twin. An always-taker, by contrast, is a mother who would always have three children regardless of twinning at the second birth. The nested IV assumption states that a complier in the absence of the birth control policy would remain a complier under the policy. Indeed, Guo et al. (2025) made this assumption in their empirical studies, although they did not formally frame the problem under a nested IV structure.

While conventional instrumental variable analysis identifies the treatment effect among compliers, an analysis using a pair of nested IVs can further distinguish treatment effects among two subgroups: always-compliers—those who comply under both IVs—and switchers—those who shift from non-compliers under a weaker IV to compliers under a stronger IV (Wang et al., 2024). These subgroups are particularly relevant for policymaking because always-compliers represent individuals who are consistently responsive to encouragement, whereas switchers are those whose treatment adherence could be influenced through stronger incentives or interventions. For instance, in a clinical trial setting, switchers may represent participants whose treatment uptake could plausibly be improved through enhanced or more intensive encouragement strategies. Estimating treatment effects within

these subgroups can inform implementation science—a key priority at the National Institutes of Health—and guide the design of implementation trials by revealing potential effect heterogeneity. For example, if switchers demonstrate a substantial treatment effect, this would support more proactive efforts to enhance adherence and ensure that evidence-based interventions reach those most likely to benefit.

### 1.3 A design-based framework for nested IV analysis

In this paper, we develop a design-based framework for nested IV analysis that has three main components. First, we introduce a pair-of-pairs design that mimics a finely stratified experiment under a hierarchical, two-stage randomization scheme. For instance, in a multicentre clinical trial, participants are first randomized to a clinical site and then, within each site, randomized to receive either treatment or control. We construct such designs by efficiently solving a network flow problem on a tripartite network (Karmakar et al., 2019; Zhang et al., 2023).

Second, we develop design-based inference for the sample average treatment effect among always-compliers (ACO-SATE) and switchers (SW-SATE) under the pair-of-pairs nested IV design. Unlike the approach of Wang et al. (2024), inference developed in this article relies solely on the IV assignment mechanism and does not require modeling any component of the potential outcomes. Through simulation studies and a case study, we show that this design-based method remains robust even in challenging scenarios, such as small sample sizes, low proportions of switchers, or binary endpoints with few observed events.

Third, in our case study, the assignment of participants to one IV pair versus the other—such as attending a clinical site in Seattle versus Portland—need not be randomized, even though the IV assignment within a site is randomized; see Stuart et al. (2011) for a related discussion on trial selection probability. To address this setting, we introduce a novel *partly biased randomization scheme* and study design-based inference under this scheme.

The rest of the article is organized as follows. Section 2 describes the proposed pair-of-pairs design and proposes a computationally efficient method to achieve the design. Section

3 describes the potential outcomes and estimands of interest. Design-based inference under randomization and a novel partly biased randomization scheme is studied in Section 4. We present simulation studies in Section 5 and apply the proposed design and analysis tools to the PLCO trial in Section 6. Section 7 concludes with a discussion. Technical proofs can be found in the Supplemental Materials, and code accompanying the article can be found via the following link: <https://github.com/Zhe-Chen-1999/Design-Based-Nested-IV>.

## 2 Study design

### 2.1 Pair-of-pairs nested IV design

Our proposed pair-of-pairs nested IV (PoP-NIV) design consists of  $I$  matched strata, indexed by  $i = 1, \dots, I$ , each consisting of two matched pairs, indexed by  $j = 1, 2$ . Each matched pair  $j$  in stratum  $i$  consists of two units indexed by  $k$ . Two units in one pair in the matched stratum are assigned one binary IV, denoted as  $\{0_a, 1_a\}$ , and those in the other pair are assigned the other binary IV, denoted as  $\{0_b, 1_b\}$ . We use  $ijk$ ,  $i = 1, \dots, I$ ,  $j = 1, 2$ ,  $k = 1, 2$ , to index the  $k$ -th participant in the matched pair  $j$  in the  $i$ -th stratum.

A matching algorithm  $\mathbf{M}$  embeds the observational data into a hypothetical, two-stage randomized encouragement experiment as follows. Within each matched stratum  $i$ , one pair is randomized to the IV dose pair  $(0_a, 1_a)$  and the other to  $(0_b, 1_b)$ . Then, within the pair randomized to  $(0_a, 1_a)$ , two units are further randomized to  $0_a$  or  $1_a$ . Analogously, within the pair randomized to  $(0_b, 1_b)$ , two units are further randomized to  $0_b$  or  $1_b$ . Let  $\mathbf{Z}_i = (Z_{i11}, Z_{i12}, Z_{i21}, Z_{i22})$  denote the IV assignment vector of stratum  $i$  and

$$\Omega = \{(1_a, 0_a, 1_b, 0_b), (0_a, 1_a, 1_b, 0_b), (1_a, 0_a, 0_b, 1_b), (0_a, 1_a, 0_b, 1_b), \\ (1_b, 0_b, 1_a, 0_a), (1_b, 0_b, 0_a, 1_a), (0_b, 1_b, 1_a, 0_a), (0_b, 1_b, 0_a, 1_a)\}$$

denote the set of  $2^3 = 8$  possible configurations of the IV assignment vector  $\mathbf{Z}_i$ . Finally, let  $\mathbf{x}_{ijk}$  denote participant  $ijk$ 's observed covariates and  $\mathbf{X}$  the covariate matrix for all  $4I$  participants.

In design-based IV analysis, the probability of IV assignment provides the sole basis of statistical inference. Randomization assumption is often a starting point for analysis

(Rosenbaum, 2002; Imbens and Rosenbaum, 2005; Small and Rosenbaum, 2008), followed by a biased randomization scheme that allows the IV to deviate from the randomization scheme by at most some controlled amount (Baiocchi et al., 2010; Fogarty et al., 2021). The randomization assumption in a finite-sample, pair-of-pairs nested IV design can be formally stated as follows:

**Assumption 1. (*Randomization Assumption in a PoP-NIV Design*).** *IV assignments across matched strata are assumed to be independent of each other, with  $\Pr(\mathbf{Z}_i = \mathbf{a} \mid \mathbf{X}, M) = 1/8$ , for all  $\mathbf{a} \in \Omega$ .*

In an integrated analysis of RCTs from multiple centres or studies, the randomization assumption may be violated, for instance, if there exist factors that simultaneously affect outcomes of interest and participants’ selection into different study centres (e.g., choosing to enroll at a clinical site in Seattle not Portland) or different studies (e.g., choosing to participate in one study not the other). We will discuss and study how to relax the randomization assumption in Section 4.2.

## 2.2 PoP-NIV design in a study of colorectal cancer screening

We illustrate the proposed PoP-NIV design using the PLCO Cancer Screening Trial. Supplemental Material C summarizes data of study participants who enrolled at the Henry Ford Health System before and after 1997 where the trial consent policy underwent a major shift, and the compliance rate was observed to increase massively from 50% to 80% (Marcus et al., 2014; Wang et al., 2024). Table 1 summarizes the PoP-NIV design applied to the PLCO trial data. The design consists of  $I = 3071$  matched strata, where each stratum consists of two pairs: in the first pair, two participants enrolled in the study prior to 1997 and were each randomized to the treatment group (cancer screening) or the control group (standard of care), while in the second pair, two participants enrolled in the study after 1997 and were each randomized to the treatment group or the control group. The match was constructed using an efficient, network-flow-based algorithm in less than 2 minutes on a standard laptop, the details of which are to be elaborated on in the next subsection.

Table 1: Covariate balance after matching. Mean (SD) are reported for continuous variables; Count (percentage) are reported for categorical variables.

	Prior to 1997 ( $G = a$ )		After 1997 ( $G = b$ )		$P$ -value
	Control arm	Treatment arm	Control arm	Treatment arm	
Sample size	3071	3071	3071	3071	
Treatment uptake (=Screening) (%)	0 ( 0.0)	1602 (52.2)	0 ( 0.0)	2422 (78.9)	<0.001
Age (%)					1.000
$\leq 60$	1031 (33.6)	1031 (33.6)	1031 (33.6)	1031 (33.6)	
(60, 65]	1092 (35.6)	1092 (35.6)	1092 (35.6)	1092 (35.6)	
(65, 70]	650 (21.2)	650 (21.2)	650 (21.2)	650 (21.2)	
$> 70$	298 ( 9.7)	298 ( 9.7)	298 ( 9.7)	298 ( 9.7)	
Age	63.31 (4.84)	63.33 (4.85)	63.08 (4.98)	63.09 (4.98)	0.081
Sex (=Male) (%)	1185 (38.6)	1178 (38.4)	1195 (38.9)	1190 (38.7)	0.975
Race (=Minority) (%)	520 (16.9)	518 (16.9)	496 (16.2)	510 (16.6)	0.841
Education (%)					0.381
No high school	334 (10.9)	336 (10.9)	297 ( 9.7)	295 ( 9.6)	
High school	1192 (38.8)	1182 (38.5)	1173 (38.2)	1189 (38.7)	
College or above	1545 (50.3)	1553 (50.6)	1601 (52.1)	1587 (51.7)	
Smoking status (%)					0.948
Non-smoker	1309 (42.6)	1304 (42.5)	1328 (43.2)	1332 (43.4)	
Current smoker	415 (13.5)	401 (13.1)	408 (13.3)	418 (13.6)	
Former smoker	1347 (43.9)	1366 (44.5)	1335 (43.5)	1321 (43.0)	
BMI ( $> 25$ ) (%)	2095 (68.2)	2102 (68.4)	2135 (69.5)	2096 (68.3)	0.654

We assessed covariate balance across the four groups using standard multiple-group comparison tests:  $\chi^2$  tests for categorical variables and one-way analysis of variance (ANOVA) for continuous variables. We highlight two key observations. First, the compliance rate—defined as the difference between the proportion of treatment-group participants receiving their first scheduled flexible sigmoidoscopy screening and the corresponding proportion in the control group—was markedly lower among participants enrolled before 1997 compared with those enrolled afterward (52.2% vs. 78.9%). Second, for all covariates listed in Table 1, no statistically significant differences were detected at the conventional 0.05 level, indicating that the design adequately balanced observed covariates, emulating the target randomized controlled trial. Nonetheless, as in any matched design of observational data, balance on unmeasured covariates cannot be guaranteed. In particular, unobserved factors related to clinical outcomes and to participants’ decision to enroll before versus after 1997 may still be imbalanced, in contrast to what would be expected in a genuine randomized controlled trial.



### 2.3 A computationally efficient algorithm constructing matched strata

The design in Table 1 was constructed using a modified network-flow-based tripartite matching algorithm (Karmakar et al., 2019; Zhang et al., 2023). The matching structure is represented as a four-layer network, in addition to a source code  $\xi$  and a sink node  $\bar{\xi}$ , as illustrated in Figure 1. Four layers of nodes in the network consist of (1) nodes  $\{\tau_1^a, \dots, \tau_{T_a}^a\}$  corresponding to  $|T_a|$  units assigned to the IV dose  $Z = 1_a$ , (2) nodes  $\{\gamma_1^a, \dots, \gamma_{C_a}^a\}$  corresponds to  $|C_a|$  units assigned to  $Z = 0_a$ , (3) nodes  $\{\tau_1^b, \dots, \tau_{T_b}^b\}$  corresponding to  $|T_b|$  units assigned to  $Z = 1_b$ , and (4) nodes  $\{\gamma_1^b, \dots, \gamma_{C_b}^b\}$  corresponding to  $|C_b|$  units assigned to  $Z = 0_b$ . The resulting network then contains  $T_a + C_a + T_b + C_b + 2$  vertices  $\mathcal{V}$ , connected by a total of  $|\mathcal{E}| = T_a + T_a C_a + C_a T_b + T_b C_b + C_b$  edges of the following form:

$$\mathcal{E} = \left\{ (\xi, \tau_t^a), (\tau_t^a, \gamma_c^a), (\gamma_c^a, \tau_{t'}^b), (\tau_{t'}^b, \gamma_{c'}^b), (\gamma_{c'}^b, \bar{\xi}), t = 1, \dots, T_a, c = 1, \dots, C_a, \right. \\ \left. t' = 1, \dots, T_b, c' = 1, \dots, C_b \right\}.$$




Figure 1: Network-flow representation of proposed pair-of-pairs design. Nodes  $\{\tau_1^a, \dots, \tau_4^a\}$  represent units assigned  $Z = 1_a$ ;  $\{\gamma_1^a, \dots, \gamma_5^a\}$  are assigned  $Z = 0_a$ ,  $\{\tau_1^b, \dots, \tau_3^b\}$  are assigned  $Z = 1_b$ , and  $\{\gamma_1^b, \dots, \gamma_6^b\}$  are assigned  $Z = 0_b$ . The bold blue lines correspond to two matched strata, each consisting of a pair of pairs:  $\{(\tau_1^a, \gamma_2^a), (\tau_3^b, \gamma_1^b)\}$  and  $\{(\tau_3^a, \gamma_3^a), (\tau_2^b, \gamma_6^b)\}$

Each edge  $e \in \mathcal{E}$  has unit capacity  $\text{cap}(e) = 1$ . A *feasible integral flow*  $f(\cdot)$  assigns a nonnegative integer value to each edge, subject to the following constraints:

- Capacity constraints:  $0 \leq f(e) \leq \text{cap}(e)$ , for all  $e \in \mathcal{E}$ ;
- Supply–demand balance: all flow units emitted by the source  $\xi$  are absorbed at the sink  $\bar{\xi}$ , i.e.,  $\sum_{t=1}^{T_a} f(\xi, \tau_t^a) = \sum_{c'=1}^{C_b} f(\gamma_{c'}^b, \bar{\xi}) = I \leq \min\{T_a, T_b, C_a, C_b\}$ , where  $I$

determines the number of matched strata in the final design;

- Flow conservation: for all intermediate vertices  $b \in \mathcal{V} \setminus \{\xi, \bar{\xi}\}$ , the inflow equals the outflow:

$$\sum_{(a,b) \in \mathcal{E}} f(a,b) = \sum_{(b,c) \in \mathcal{E}} f(b,c).$$

Under these constraints, a feasible integral flow  $f(\cdot)$  encodes a set of matched strata, each containing two treated-control pairs of the form:

$$\mathcal{M}(f) = \left\{ \left\{ (\tau_t^a, \gamma_c^a), (\tau_{t'}^b, \gamma_{c'}^b) \right\} : f(\tau_t^a, \gamma_c^a) = f(\gamma_c^a, \tau_{t'}^b) = f(\tau_{t'}^b, \gamma_{c'}^b) = 1 \right\}.$$

In the simple network illustrated in Figure 1, blue edges represent one feasible flow when constructing  $I = 2$  matched strata:  $\{(\tau_1^a, \gamma_2^a), (\tau_3^b, \gamma_1^b)\}$  and  $\{(\tau_3^a, \gamma_3^a), (\tau_2^b, \gamma_6^b)\}$ .

Each edge is further associated with a cost, e.g., rank-based, robust Mahalanobis distance calculated from baseline covariates (Rosenbaum, 2010). Let  $\delta_{\tau_t^g, \gamma_c^g}(\mathbf{x})$  denote the distance between treated unit  $\tau_t^g$  and control unit  $\gamma_c^g$  on covariates  $\mathbf{x}$ , for  $t = 1, \dots, T_g$ ,  $c = 1, \dots, C_g$ , and  $g \in \{a, b\}$ , and  $\delta_{\gamma_c^a, \tau_t^b}(\mathbf{x})$  be defined similarly. The total cost associated with a feasible flow  $f(\cdot)$  then equals:

$$\text{cost}(f) := \sum_{f(\tau_t^a, \gamma_c^a)=1} \delta_{\tau_t^a, \gamma_c^a}(\mathbf{x}) + \sum_{f(\gamma_c^a, \tau_{t'}^b)=1} \delta_{\gamma_c^a, \tau_{t'}^b}(\mathbf{x}) + \sum_{f(\tau_{t'}^b, \gamma_{c'}^b)=1} \delta_{\tau_{t'}^b, \gamma_{c'}^b}(\mathbf{x}).$$

A feasible flow is said to be optimal if it minimizes  $\text{cost}(f)$ . As described in more details in Zhang et al. (2023), a standard polynomial-time, minimum-cost network flow algorithm can be used to find the feasible flow  $f$  with the minimum cost, which then yields the pair-of-pairs design displayed in Table 1.

### 3 Notation and causal estimands

#### 3.1 Potential outcomes; identification assumptions; principal stratification

We formalize the causal estimands and identification assumptions under the potential outcomes framework (Neyman, 1923; Rubin, 1974). First, we adopt Rubin’s Stable Unit Treatment Value Assumption (SUTVA), which states that (i) the potential outcome of a participant does not depend on the treatment assignment of others; and (2) there is only

one version of the treatment assignment (Rubin, 1980, 1986). Under SUTVA, we define the following potential treatment received for each participant indexed by  $ijk$ .

**Definition 1** (Potential treatment received). *Let  $D_{ijk}(Z = z)$  denote participant  $ijk$ 's potential treatment received under IV level  $z \in \{0_a, 0_b, 1_a, 1_b\}$  as follows:*

$$\begin{aligned} d_{C^a_{ijk}} &\equiv D_{ijk}(Z = 0_a), & d_{T^a_{ijk}} &\equiv D_{ijk}(Z = 1_a), \\ d_{C^b_{ijk}} &\equiv D_{ijk}(Z = 0_b), & d_{T^b_{ijk}} &\equiv D_{ijk}(Z = 1_b). \end{aligned}$$

In any given dataset, only the actual treatment received,  $D_{ijk} = d_{C^a_{ijk}}\mathbb{1}\{Z_{ijk} = 0_a\} + d_{T^a_{ijk}}\mathbb{1}\{Z_{ijk} = 1_a\} + d_{C^b_{ijk}}\mathbb{1}\{Z_{ijk} = 0_b\} + d_{T^b_{ijk}}\mathbb{1}\{Z_{ijk} = 1_b\}$ , is observed for each participant.

Analogously, Definition 2 defines potential outcomes for each participant:

**Definition 2** (Potential outcomes). *Let  $R_{ijk}(D_{ijk}(Z_{ijk}), Z_{ijk})$  denote  $ijk$ 's potential outcome under IV assignment  $Z_{ijk}$  and treatment received  $D_{ijk}(Z_{ijk})$ . We make the standard exclusion restriction assumption so that  $R_{ijk}(D_{ijk}(Z_{ijk}) = d, Z_{ijk} = z) = R_{ijk}(D_{ijk}(Z_{ijk}) = d, Z_{ijk} = z')$ ,  $\forall d, z, z'$ . We write  $R_{ijk}(Z_{ijk})$  as a shorthand for  $R_{ijk}(D_{ijk}(Z_{ijk}), Z_{ijk})$ . Each participant  $ijk$  is associated with the following 4 potential outcomes:*

$$\begin{aligned} r_{C^a_{ijk}} &\equiv R_{ijk}(Z = 0_a), & r_{T^a_{ijk}} &\equiv R_{ijk}(Z = 1_a), \\ r_{C^b_{ijk}} &\equiv R_{ijk}(Z = 0_b), & r_{T^b_{ijk}} &\equiv R_{ijk}(Z = 1_b). \end{aligned}$$

Let  $R_{ijk} = r_{C^a_{ijk}}\mathbb{1}\{Z_{ijk} = 0_a\} + r_{T^a_{ijk}}\mathbb{1}\{Z_{ijk} = 1_a\} + r_{C^b_{ijk}}\mathbb{1}\{Z_{ijk} = 0_b\} + r_{T^b_{ijk}}\mathbb{1}\{Z_{ijk} = 1_b\}$  denote the observed outcome for  $ijk$ .

Following Angrist et al. (1996), participant  $ijk$  is said to be a complier with respect to the IV dose pair  $(0_g, 1_g)$ , for  $g \in \{a, b\}$ , if  $(d_{T^g_{ijk}}, d_{C^g_{ijk}}) = (1, 0)$ , an always-taker if  $(d_{T^g_{ijk}}, d_{C^g_{ijk}}) = (1, 1)$ , a never-taker if  $(d_{T^g_{ijk}}, d_{C^g_{ijk}}) = (0, 0)$ , and a defier if  $(d_{T^g_{ijk}}, d_{C^g_{ijk}}) = (0, 1)$ , where  $d_{T^g_{ijk}}$  and  $d_{C^g_{ijk}}$  are defined in Definition 1. In IV analysis, a common assumption is that participants are not less likely to take the treatment when offered treatment rather than control (Angrist et al., 1996). We adopt this assumption for each IV pair  $(\{0_a, 1_a\} \text{ or } \{0_b, 1_b\})$  and refer to it as the partial monotonicity assumption.

**Assumption 2** (Partial monotonicity). *For each participant indexed by  $ijk$ , we have  $d_{T^g_{ijk}} \geq d_{C^g_{ijk}}$ ,  $g \in \{a, b\}$ .*

Under this partial monotonicity assumption, defiers under either IV pair are assumed not to exist, and the compliance rate under IV pair  $(0_g, 1_g)$  is defined as follows:

$$\iota_g = \frac{1}{4I} \sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 (d_{T^g_{ijk}} - d_{C^g_{ijk}}), \quad g \in \{a, b\},$$

which is the sample average treatment effect of the binary IV  $(0_g, 1_g)$  on treatment received.

Finally, we make the *nested IV assumption* below to impose an additional structure on potential treatment received under two versions of the IV assignment (Wang et al., 2024).

**Assumption 3** (Nested IV). *For each participant indexed by  $ijk$ ,  $(d_{C^a_{ijk}}, d_{T^a_{ijk}}) = (0, 1)$  implies  $(d_{C^b_{ijk}}, d_{T^b_{ijk}}) = (0, 1)$ .*

In words, Assumption 3 says that a participant who is a complier under a weaker IV pair, that is,  $(0_a, 1_a)$ , would remain a complier under a stronger IV pair, that is,  $(0_b, 1_b)$ . The nested IV assumption has a testable implication. Under Assumptions 2 and 3, we would necessarily have  $\iota_b \geq \iota_a$ ; hence, by testing the one-sided null hypothesis  $H_0 : \iota_b \geq \iota_a$ , one could assess the validity of Assumptions 2 and 3.

A participant's compliance status is determined jointly by both IV pairs,  $(0_a, 1_a)$  and  $(0_b, 1_b)$ . In principle, this yields  $2^4 = 16$  possible principal strata. However, under Assumptions 2 and 3, the number is reduced from 16 to  $6^1$  (Wang et al., 2024). These 6 principal strata are: (i) SWitchers (SW), who are non-compliers (that is, always-takers or never-takers) under the weaker IV pair  $(0_a, 1_a)$  but compliers under the stronger IV pair  $(0_b, 1_b)$ , with  $(d_{T^a_{ijk}}, d_{C^a_{ijk}}) \in \{(1, 1), (0, 0)\}$  and  $(d_{T^b_{ijk}}, d_{C^b_{ijk}}) = (1, 0)$ ; (ii) Always-COmpliers (ACO), who comply with the assigned treatment under both IV pairs  $(0_a, 1_a)$  and  $(0_b, 1_b)$ , with  $(d_{T^a_{ijk}}, d_{C^a_{ijk}}) = (d_{T^b_{ijk}}, d_{C^b_{ijk}}) = (1, 0)$ ; (iii) Always-Taker-Never-Takers (AT-NT), who always take the treatment under  $\{0_a, 1_a\}$  but never take the treatment under  $\{0_b, 1_b\}$ , with  $(d_{T^a_{ijk}}, d_{C^a_{ijk}}) = (1, 1)$  and  $(d_{T^b_{ijk}}, d_{C^b_{ijk}}) = (0, 0)$ ; (iv) Always-Always-Takers (AAT), who are always-takers under both IV pairs  $(0_a, 1_a)$  and  $(0_b, 1_b)$ , with  $(d_{T^a_{ijk}}, d_{C^a_{ijk}}) = (d_{T^b_{ijk}}, d_{C^b_{ijk}}) = (1, 1)$ ; (v) Never-Taker-Always-Takers (NT-AT), who never take treatment under  $\{0_a, 1_a\}$  but always take it under  $\{0_b, 1_b\}$ , with  $(d_{T^a_{ijk}}, d_{C^a_{ijk}}) = (0, 0)$  and

---

<sup>1</sup>More precisely, Assumptions 2 and 3 reduce the number of principal strata from 16 to 7. In what follows, we consider only 6 principal strata, as two of the original strata are combined into a single stratum of switchers.

$(d_{T^{b_{ijk}}}, d_{C^{b_{ijk}}}) = (1, 1)$ ; and (vi) Always-Never-Takers (ANT), who never take the treatment under either IV pair  $(0_a, 1_a)$  or  $(0_b, 1_b)$ , with  $(d_{T^{a_{ijk}}}, d_{C^{a_{ijk}}}) = (d_{T^{b_{ijk}}}, d_{C^{b_{ijk}}}) = (0, 0)$ .

Finally, Definition 3 defines the “per-protocol” potential outcomes.

**Definition 3** (Per-protocol potential outcomes). *Let*

$$r_{d=0,ijk} \equiv R_{ijk}(D = 0) \quad \text{and} \quad r_{d=1,ijk} \equiv R_{ijk}(D = 1)$$

*denote the potential outcomes had participant  $ijk$  taken the control or treatment.*

Unlike  $(r_{T^g_{ijk}}, r_{C^g_{ijk}})$ ,  $g \in \{a, b\}$ , which depend on the IV pair,  $(r_{d=0,ijk}, r_{d=1,ijk})$  do not depend on the IV and are arguably the ultimate quantity of interest.

### 3.2 Always-complier sample average treatment effect (ACO-SATE)

Equipped with the potential outcomes defined in Definitions 1 and 2, we are ready to define the target causal estimands. Our first estimand of interest is the following “effect ratio”-style estimand (Baiocchi et al., 2010; Kang et al., 2018; Zhang et al., 2022; Chen et al., 2025):

$$\kappa = \frac{\sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 (r_{T^{a_{ijk}}} - r_{C^{a_{ijk}}})}{\sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 (d_{T^{a_{ijk}}} - d_{C^{a_{ijk}}})},$$

which, under the partial monotonicity assumption  $d_{T^{a_{ijk}}} \geq d_{C^{a_{ijk}}}$  and the nested IV assumption, equals the SATE among the always-complier subgroup, that is,

$$\text{ACO-SATE} = \frac{1}{n_{\text{ACO}}} \sum_{ijk \in \text{ACO}} \{r_{d=1,ijk} - r_{d=0,ijk}\},$$

where  $n_{\text{ACO}}$  denotes the number of always-compliers in the cohort, and  $(r_{d=1,ijk}, r_{d=0,ijk})$  are “per-protocol” outcomes defined in Definition 3.

### 3.3 Switcher sample average treatment effect (SW-SATE)

Our second target estimand is the following ratio of difference-in-differences:

$$\lambda = \frac{\sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 (r_{T^{b_{ijk}}} - r_{C^{b_{ijk}}}) - (r_{T^{a_{ijk}}} - r_{C^{a_{ijk}}})}{\sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 (d_{T^{b_{ijk}}} - d_{C^{b_{ijk}}}) - (d_{T^{a_{ijk}}} - d_{C^{a_{ijk}}})}, \quad (1)$$

where the numerator denotes the difference in the sample average treatment effect of IV on the outcome between two IV pairs, and the denominator denotes that on the treatment received.

The estimand  $\lambda$  is well-defined provided that the denominator,  $\sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 (d_{T^b_{ijk}} - d_{C^b_{ijk}}) - (d_{T^a_{ijk}} - d_{C^a_{ijk}})$ , does not equal 0; that is, the sample average treatment effect of IV on treatment received is different between two IV pairs.

In the absence of the partial monotonicity assumption and the nested IV assumption, the parameter  $\lambda$  can be interpreted as follows: for every hundred additional people converted by the stronger IV  $(0_b, 1_b)$  to take the treatment, the intention-to-treat effect is increased by  $100 \times \lambda$ .

We further define the sample average treatment effect among switchers as follows:

$$\text{SW-SATE} = \frac{1}{n_{\text{SW}}} \sum_{ijk \in \text{SW}} \{r_{d=1,ijk} - r_{d=0,ijk}\}, \quad (2)$$

where  $n_{\text{SW}}$  denotes the number of switchers in the cohort, and  $(r_{d=1,ijk}, r_{d=0,ijk})$  are “per-protocol” outcomes defined in Definition 3.

Under the partial monotonicity assumption and the nested IV assumption, we have  $\lambda = \text{SW-SATE}$ , as formalized in Proposition 1.

**Proposition 1.** *Let  $\lambda$  and SW-SATE be defined as in (1) and (2), respectively. Under Assumptions 2 and 3, we have  $\lambda = \text{SW-SATE}$ .*

Proposition 1 holds because, for the principal strata AT–NT, AAT, NT–AT, and ANT, under either IV, the IV has no effect on treatment received and, consequently, no effect on the outcome. Moreover, for the always-complier (ACO) principal stratum—participants who comply under either IV pair—both the numerator and denominator in  $\lambda$  are equal to 0. Therefore, only the switcher subgroup contributes to  $\lambda$ , and we have:

$$\lambda = \frac{\sum_{ijk \in \text{SW}} (r_{T^b_{ijk}} - r_{C^b_{ijk}})}{\sum_{ijk \in \text{SW}} (d_{T^b_{ijk}} - d_{C^b_{ijk}})} = \frac{\sum_{ijk \in \text{SW}} R_{ijk}(D=1) - R_{ijk}(D=0)}{\sum_{ijk \in \text{SW}} (1 - 0)} = \text{SW-SATE}, \quad (3)$$

where the first equality holds because under the weaker IV pair  $\{0_a, 1_a\}$ , switchers are never-takers or always-takers with a zero intention-to-treat effect, and the second equality holds because under the stronger IV pair  $\{0_b, 1_b\}$ , switchers become compliers.

Both causal parameters,  $\kappa$  and  $\lambda$ , involve contrasts of potential outcomes. The estimand  $\kappa$  depends on  $(d_{T^a_{ijk}}, r_{T^a_{ijk}})$  and  $(d_{C^a_{ijk}}, r_{C^a_{ijk}})$ ; for each participant assigned to the weaker

IV pair, either  $(d_{T^{a_{ijk}}}, r_{T^{a_{ijk}}})$  or  $(d_{C^{a_{ijk}}}, r_{C^{a_{ijk}}})$  is observed, whereas for those assigned to the stronger IV pair, neither is observed. Similarly, the estimand  $\lambda$  involves 4 sets of potential outcomes— $(d_{T^{a_{ijk}}}, r_{T^{a_{ijk}}})$ ,  $(d_{C^{a_{ijk}}}, r_{C^{a_{ijk}}})$ ,  $(d_{T^{b_{ijk}}}, r_{T^{b_{ijk}}})$ ,  $(d_{C^{b_{ijk}}}, r_{C^{b_{ijk}}})$ —of which only one set is observed per participant. Consequently, statistical inference is required for both estimands. We develop design-based inference for  $\kappa$  and  $\lambda$  in the next section.

## 4 Design-based inference for ACO-SATE and SW-SATE

### 4.1 Inference under the randomization assumption

Write  $\mathcal{F} = \{(d_{C^{a_{ijk}}}, d_{T^{a_{ijk}}}, d_{C^{b_{ijk}}}, d_{T^{b_{ijk}}}, r_{C^{a_{ijk}}}, r_{T^{a_{ijk}}}, r_{C^{b_{ijk}}}, r_{T^{b_{ijk}}}, \mathbf{x}_{ijk}), i = 1, \dots, I, j = 1, 2, k = 1, 2\}$  and  $\mathcal{Z}$  the set containing all  $8^I$  possible IV assignments. To facilitate making inference of  $\kappa$  and  $\lambda$ , we introduce an auxiliary random variable  $Z_{ijk}^g$  for each  $g \in \{a, b\}$  as follows:  $Z_{ijk}^g = 1$  if  $Z_{ijk} = 1_g$ ,  $Z_{ijk}^g = 0$  if  $Z_{ijk} = 0_g$ , and  $Z_{ijk}^g = 1/2$  otherwise. By design, this construction ensures that  $Z_{ij1}^g + Z_{ij2}^g = 1$  for  $j \in \{1, 2\}$  and  $g \in \{a, b\}$ . The IV assignment mechanism for  $\mathbf{Z}_i = (Z_{i11}, Z_{i12}, Z_{i21}, Z_{i22})$ , as formalized by Assumption 1, determines the joint distribution of  $Z_{ijk}^g$ .

We first derive a valid level- $\alpha$  confidence interval for the difference in compliance rates between the two IV pairs, which can be interpreted as the proportion of switchers in the sample under Assumptions 2 and 3. To that end, we conduct a finite-population asymptotic analysis in which the  $4I$  units are embedded into a sequence of finite populations of increasing size (Li and Ding, 2017). This asymptotic framework forms the basis for the statistical inference developed throughout the remainder of the article.

**Proposition 2** (Inference for the proportion of switchers). *Let*

$$V_i = \sum_{j=1}^2 \sum_{k=1}^2 \left\{ \{Z_{ijk}^b D_{ijk} - (1 - Z_{ijk}^b) D_{ijk}\} - \{Z_{ijk}^a D_{ijk} - (1 - Z_{ijk}^a) D_{ijk}\} \right\},$$

$$\bar{V} = I^{-1} \sum_{i=1}^I V_i,$$

and define the variance estimator

$$S^2 = \frac{1}{I(I-1)} \sum_{i=1}^I (V_i - \bar{V})^2.$$

Under mild regularity conditions and conditional on  $\mathcal{F}$  and  $\mathcal{Z}$ , the interval

$$\left\{ c : \left| \bar{V} - c \right| \leq z_{1-\alpha/2} \sqrt{S^2} \right\}$$

is an asymptotically valid, level- $\alpha$  confidence interval for  $\iota_b - \iota_a$ , the proportion of switchers in the sample, where  $z_{1-\alpha/2}$  denotes the  $(1 - \alpha/2)$ -th quantile of the standard normal distribution.

**Remark 1** (Inference of  $\iota_g$ ). By letting  $V_i = \sum_{j=1}^2 \sum_{k=1}^2 \{Z_{ijk}^g D_{ijk} - (1 - Z_{ijk}^g) D_{ijk}\}$  in Proposition 2, we can similarly construct a level- $\alpha$  confidence interval for  $\iota_g$ , the compliance rate under IV pair  $(0_g, 1_g)$ ,  $g \in \{a, b\}$ .

Next, we consider testing the null hypothesis

$$H_0^{\text{ACO}} : \kappa = \kappa_0$$

for the ACO-SATE estimand. Theorem 1 provides an asymptotically valid, level- $\alpha$  test under the randomization scheme specified in Assumption 1.

**Theorem 1** (Inference for the SATE among always-compliers). *Let*

$$V_{i,\text{ACO}}(\kappa_0) = \sum_{j=1}^2 \sum_{k=1}^2 \left\{ Z_{ijk}^a (R_{ijk} - \kappa_0 D_{ijk}) - (1 - Z_{ijk}^a) (R_{ijk} - \kappa_0 D_{ijk}) \right\}.$$

and define the test statistic

$$T_{\text{ACO}}(\kappa_0) = I^{-1} \sum_{i=1}^I V_{i,\text{ACO}}(\kappa_0),$$

with the corresponding variance estimator

$$S_{\text{ACO}}^2(\kappa_0) = \frac{1}{I(I-1)} \sum_{i=1}^I \left\{ V_{i,\text{ACO}}(\kappa_0) - I^{-1} \sum_{i=1}^I V_{i,\text{ACO}}(\kappa_0) \right\}^2.$$

Conditional on  $\mathcal{F}$  and  $\mathcal{Z}$ , the test that rejects  $H_0^{\text{ACO}} : \kappa = \kappa_0$  when

$$|T_{\text{ACO}}(\kappa_0)| \geq z_{1-\alpha/2} \sqrt{S_{\text{ACO}}^2(\kappa_0)}$$

is an asymptotically valid, level- $\alpha$  test, under mild regularity conditions.

**Remark 2.** The level- $\alpha$  confidence interval established in Theorem 1 is also a conditionally valid level- $\alpha$  confidence interval for the effect ratio estimand restricted to the  $2I$  units assigned to  $\{0_a, 1_a\}$ , noting that these  $2I$  units constitute a random sample from the full set of  $4I$  units; see, for example, Branson (2020), for a related discussion.



**Remark 3.** The variance estimator  $S_{\text{ACO}}^2(\kappa_0)$  generally overestimates the true variance (Imai, 2008). It is unbiased for the true variance if and only if

$$\sum_{j=1}^2 \sum_{k=1}^2 \{r_{d=1,ijk} - r_{d=0,ijk} - \kappa_0\} \mathbb{1}\{S_{ijk} = \text{ACO}\}$$

is constant across all strata  $i = 1, \dots, I$ . A sufficient condition for this to hold is that the treatment effect among always-compliers is constant.

Finally, we move on to making inference for the SW-SATE. Theorem 2 establishes an asymptotically valid, level- $\alpha$  test for the null hypothesis

$$H_0^{\text{SW}} : \lambda = \lambda_0.$$

**Theorem 2** (Inference for the SATE among switchers). *Let*

$$\begin{aligned} V_{i,\text{SW}}(\lambda_0) &= \sum_{j=1}^2 \sum_{k=1}^2 \{Z_{ijk}^b(R_{ijk} - \lambda_0 D_{ijk}) - (1 - Z_{ijk}^b)(R_{ijk} - \lambda_0 D_{ijk})\} \\ &\quad - \sum_{j=1}^2 \sum_{k=1}^2 \{Z_{ijk}^a(R_{ijk} - \lambda_0 D_{ijk}) - (1 - Z_{ijk}^a)(R_{ijk} - \lambda_0 D_{ijk})\}, \end{aligned}$$

and define the test statistic

$$T_{\text{SW}}(\lambda_0) = I^{-1} \sum_{i=1}^I V_{i,\text{SW}}(\lambda_0),$$

with the corresponding variance estimator

$$S_{\text{SW}}^2(\lambda_0) = \frac{1}{I(I-1)} \sum_{i=1}^I \left\{ V_{i,\text{SW}}(\lambda_0) - I^{-1} \sum_{i=1}^I V_{i,\text{SW}}(\lambda_0) \right\}^2.$$

Under mild regularity conditions and conditional on  $\mathcal{F}$  and  $\mathcal{Z}$ , the test that rejects  $H_0^{\text{SW}} : \lambda = \lambda_0$  when

$$|T_{\text{SW}}(\lambda_0)| \geq z_{1-\alpha/2} \sqrt{S_{\text{SW}}^2(\lambda_0)}$$

is an asymptotically valid, level- $\alpha$  test.

**Remark 4** (Conservativeness of the variance estimator). *As with ACO-SATE, the variance estimator  $S_{\text{SW}}^2(\lambda_0)$  for SW-SATE in general overestimates the true variance of the test statistic. It is unbiased if and only if*

$$\sum_{j=1}^2 \sum_{k=1}^2 \{r_{d=1,ijk} - r_{d=0,ijk} - \lambda_0\} \mathbb{1}(S_{ijk} = \text{SW})$$

is constant across all strata  $i = 1, \dots, I$ . A sufficient condition for this to hold is when the treatment effect is constant among switchers. In practice, such conditions may be stringent,

and therefore  $S_{\text{SW}}^2(\lambda_0)$  typically overestimates the true variance of the test statistic  $T_{\text{SW}}(\lambda_0)$ . However, as we will demonstrate in the simulation studies, the extent to which  $S_{\text{ACO}}^2(\kappa_0)$  in Theorem 1 and  $S_{\text{SW}}^2(\lambda_0)$  are overestimated is relatively small across many practical scenarios; consequently, inference procedures based on Theorems 1 and 2 are often not overly conservative.

## 4.2 A partly biased randomization scheme

In an integrated analysis of data from multiple sites in a multicentre clinical trial, treatment assignment is randomized within each site—either with or without matching on observed covariates—whereas “site selection” may not be randomized, even after accounting for observed covariates. To be more specific, among the 8 possible IV assignment configurations in  $\Omega$ , those in

$$\Omega_1 = \{(1_a, 0_a, 1_b, 0_b), (0_a, 1_a, 1_b, 0_b), (1_a, 0_a, 0_b, 1_b), (0_a, 1_a, 0_b, 1_b)\}$$

are equiprobable, and we denote this probability as  $\pi_{ia} = \Pr(\mathbf{Z}_i = \mathbf{e} \mid \mathbf{X}, \mathbf{M})$  for  $\mathbf{e} \in \Omega_1$ .

Similarly, the 4 IV assignments in

$$\Omega_2 = \{(1_b, 0_b, 1_a, 0_a), (1_b, 0_b, 0_a, 1_a), (0_b, 1_b, 1_a, 0_a), (0_b, 1_b, 0_a, 1_a)\}$$

are equiprobable. If we use  $\pi_{ib} = \Pr(\mathbf{Z}_i = \mathbf{e} \mid \mathbf{X}, \mathbf{M})$  for  $\mathbf{e} \in \Omega_2$  to denote this probability, then  $\pi_{ia} + \pi_{ib} = 1/4$ .

We follow the Rosenbaum sensitivity analysis model (Rosenbaum, 2002) and quantify the maximum deviation from a randomization scheme for each matched strata  $i$  as follows:

$$\frac{1}{4(1 + \Gamma)} \leq \pi_{ia} \leq \frac{\Gamma}{4(1 + \Gamma)}, \quad (4)$$

or equivalently:

$$\frac{1}{\Gamma} \leq \frac{\pi_{ia}}{\frac{1}{4} - \pi_{ia}} \leq \Gamma. \quad (5)$$

Under this model,  $\Gamma = 1$  corresponds to randomization at the “trial” or “clinical site” level, in which case all elements in  $\Omega = \Omega_1 \cup \Omega_2$  are equiprobable and Assumption 1 holds. As  $\Gamma > 1$  increases, the potential deviation from randomization within each matched stratum  $i$  grows, and Equation (4) (equivalently, Equation (5)) specifies a uniform upper bound on that deviation.

Definition 4 formalizes this partly biased randomization scheme.

**Definition 4** (Partly biased randomization scheme). *A partly biased randomization scheme indexed by  $\Gamma \geq 1$ , denoted as  $\mathcal{M}_\Gamma$ , refers to the set of probability distributions on  $\Omega = \Omega_1 \cup \Omega_2$  that satisfy the restriction in Equation (4) or equivalently Equation (5).*

### 4.3 Inference under the partly biased randomization scheme

To facilitate inference under the partly biased randomization scheme  $\mathcal{M}_\Gamma$ , we first introduce an alternative characterization of the partly biased randomization scheme.

Fix  $\Gamma \geq 1$ . Define  $A_i = 1$  if, in stratum  $i$ , pair  $j = 1$  is assigned to the IV pair  $\{0_a, 1_a\}$  and pair  $j = 2$  to  $\{0_b, 1_b\}$ , and let  $A_i = 0$  if the assignments are reversed. Let  $A_i$  satisfy

$$\frac{1}{1 + \Gamma} \leq P(A_i = 1) \leq \frac{\Gamma}{1 + \Gamma},$$

for  $i = 1, \dots, I$ .

For all  $i = 1, \dots, I$ ,  $j = 1, 2$ , further define the random variable  $T_{ij}$  as follows:

$$T_{ij} = \begin{cases} +1, & \text{if the unit } ij1 \text{ is assigned to } 1_a \text{ or } 1_b \text{ and } ij2 \text{ to } 0_a \text{ or } 0_b, \\ -1, & \text{if the unit } ij1 \text{ is assigned to } 0_a \text{ or } 0_b \text{ and } ij2 \text{ to } 1_a \text{ or } 1_b. \end{cases}$$

By construction,  $T_{ij}$  is independent of  $A_i$ , and randomization within each pair  $ij$  ensures  $P(T_{ij} = +1) = P(T_{ij} = -1) = 1/2$ . One can readily see that the partly biased randomization model  $\mathcal{M}_\Gamma$  is then fully characterized by  $\{(A_i, T_{i1}, T_{i2}), i = 1, \dots, I\}$ .

We consider testing the null hypothesis  $H_0^{\text{ACO}} : \kappa = \kappa_0$  for always-compliers under  $\mathcal{M}_\Gamma$ . For each matched stratum  $i$ , define:

$$\begin{aligned} \hat{\tau}_{i,\text{ACO}}(\kappa_0) = & A_i \cdot T_{i1} \cdot \{R_{i11} - \kappa_0 D_{i11} - (R_{i12} - \kappa_0 D_{i12})\} \\ & + (1 - A_i) \cdot T_{i2} \cdot \{R_{i21} - \kappa_0 D_{i21} - (R_{i22} - \kappa_0 D_{i22})\}, \end{aligned} \quad (6)$$

and

$$D_{i,\Gamma}^{\text{ACO}}(\kappa_0) = \hat{\tau}_{i,\text{ACO}}(\kappa_0) - \left( \frac{\Gamma - 1}{\Gamma + 1} \right) |\hat{\tau}_{i,\text{ACO}}(\kappa_0)|. \quad (7)$$

Theorem 3 shows that a valid test for  $H_0^{\text{ACO}} : \kappa = \kappa_0$  under  $\mathcal{M}_\Gamma$  can be constructed using  $\{D_{i,\Gamma}^{\text{ACO}}(\kappa_0), i = 1, \dots, I\}$ .

**Theorem 3.** *For each matched stratum  $i$ , let  $\hat{\tau}_{i,\text{ACO}}(\kappa_0)$  and  $D_{i,\Gamma}^{\text{ACO}}(\kappa_0)$  be defined as in (6) and (7), respectively. Let  $\bar{D}_{\Gamma,\text{ACO}}(\kappa_0) = I^{-1} \sum_{i=1}^I D_{i,\Gamma}^{\text{ACO}}(\kappa_0)$  be the sample mean across  $I$*

matched strata and  $S_{\Gamma, \text{ACO}}^2(\kappa_0) = \frac{1}{I(I-1)} \sum_{i=1}^I \left( D_{i, \Gamma}^{\text{ACO}}(\kappa_0) - \overline{D}_{\Gamma, \text{ACO}}(\kappa_0) \right)^2$  the corresponding variance estimator. Consider testing  $H_0^{\text{ACO}} : \kappa = \kappa_0$  against a greater-than alternative under the partly biased IV assignment model  $\mathcal{M}_{\Gamma}$ . The test that rejects  $H_0^{\text{ACO}}$  when  $\overline{D}_{\Gamma, \text{ACO}}(\kappa_0)/S_{\Gamma, \text{ACO}}(\kappa_0) \geq z_{1-\alpha}$  is an asymptotically valid level- $\alpha$  test, and the corresponding one-sided, level- $\alpha$  confidence interval can be obtained by inverting the test.

Lastly, we consider testing the null hypothesis  $H_0^{\text{SW}} : \lambda = \lambda_0$  under the model  $\mathcal{M}_{\Gamma}$ . For each matched stratum  $i$ , define:

$$\begin{aligned} \hat{\tau}_{i, \text{SW}}(\lambda_0) = & A_i \cdot \left\{ T_{i2} \cdot \{ R_{i21} - \lambda_0 D_{i21} - (R_{i22} - \lambda_0 D_{i22}) \} - T_{i1} \cdot \{ R_{i11} - \lambda_0 D_{i11} - (R_{i12} - \lambda_0 D_{i12}) \} \right\} \\ & + (1 - A_i) \cdot \left\{ T_{i1} \cdot \{ R_{i11} - \lambda_0 D_{i11} - (R_{i12} - \lambda_0 D_{i12}) \} - T_{i2} \cdot \{ R_{i21} - \lambda_0 D_{i21} - (R_{i22} - \lambda_0 D_{i22}) \} \right\}, \end{aligned}$$

and

$$D_{i, \Gamma}^{\text{SW}}(\lambda_0) = \hat{\tau}_{i, \text{SW}}(\lambda_0) - \left( \frac{\Gamma - 1}{\Gamma + 1} \right) |\hat{\tau}_{i, \text{SW}}(\lambda_0)|.$$

Theorem 4 derives a valid, level- $\alpha$  test for the null hypothesis  $H_0^{\text{SW}} : \lambda = \lambda_0$  under  $\mathcal{M}_{\Gamma}$ .

**Theorem 4.** For each matched pair  $i$ , let  $\hat{\tau}_{i, \text{SW}}(\lambda_0)$  and  $D_{i, \Gamma}^{\text{SW}}(\lambda_0)$  be defined as above. Let  $\overline{D}_{\Gamma, \text{SW}}(\lambda_0) = I^{-1} \sum_{i=1}^I D_{i, \Gamma}^{\text{SW}}(\lambda_0)$  be the sample mean across  $I$  matched strata and  $S_{\Gamma, \text{SW}}^2(\lambda_0) = \frac{1}{I(I-1)} \sum_{i=1}^I \left( D_{i, \Gamma}^{\text{SW}}(\lambda_0) - \overline{D}_{\Gamma, \text{SW}}(\lambda_0) \right)^2$  be the usual variance estimator. Consider testing  $H_0^{\text{SW}} : \lambda = \lambda_0$  against a greater-than alternative under the partly biased IV assignment model  $\mathcal{M}_{\Gamma}$ . The test that rejects  $H_0^{\text{SW}}$  when  $\overline{D}_{\Gamma, \text{SW}}(\lambda_0)/S_{\Gamma, \text{SW}}(\lambda_0) \geq z_{1-\alpha}$  is an asymptotically valid level- $\alpha$  test, and the corresponding one-sided, level- $\alpha$  confidence interval can be obtained by inverting the test.

*Proof.* We provide a sketch of the proof for Theorem 4. The proof of Theorem 3 is analogous. Proving Theorem 4 consists of two key steps. The first step is to construct a bounding variable for the random variable  $D_{i, \Gamma}^{\text{SW}}(\lambda_0)$  conditional on each of the 4 realizations of  $(T_{i1}, T_{i2})$ , which can be achieved using arguments in Fogarty (2020). Let  $U_{i, \Gamma}^{(+1, +1)}$ ,  $U_{i, \Gamma}^{(+1, -1)}$ ,  $U_{i, \Gamma}^{(-1, +1)}$ , and  $U_{i, \Gamma}^{(-1, -1)}$  denote the bounding variable for  $D_{i, \Gamma}^{\text{SW}}(\lambda_0)$  when  $(T_{i1}, T_{i2}) = (+1, +1)$ ,  $(+1, -1)$ ,  $(-1, +1)$ , and  $(-1, -1)$ , respectively. Define a random variable  $U_{i, \Gamma}$  that equals  $U_{i, \Gamma}^{(+1, +1)}$ ,  $U_{i, \Gamma}^{(+1, -1)}$ ,  $U_{i, \Gamma}^{(-1, +1)}$ , and  $U_{i, \Gamma}^{(-1, -1)}$ , each with probability 1/4. In the second step, it can be shown that, under the null hypothesis  $H_0 : \lambda = \lambda_0$ ,  $\mathbb{E} \left[ \sum_{i=1}^I U_{i, \Gamma} \right] \leq 0$ , which then

implies  $\mathbb{E}[\sum_{i=1}^I D_{i,\Gamma}^{\text{SW}}(\lambda_0)] \leq 0$  because  $D_{i,\Gamma}^{\text{SW}}(\lambda_0)$  is stochastically dominated by  $U_{i,\Gamma}$ . The full details can be found in the Supplemental Material A.  $\square$

## 5 Simulation

We have two goals in the simulation studies. Section 5.1 evaluates the finite-sample performance of the proposed tests for the SW-SATE and ACO-SATE under a randomization scheme. Section 5.2 summarizes the performance of the proposed test under the partly biased randomization scheme.

### 5.1 Validity and power of the proposed tests under a randomization scheme

#### 5.1.1 Simulation setup

We first verify the level and assess the power of the hypothesis test for the SW-SATE. We generate data for a PoP-NIV design consisting of  $I$  strata. The first factor we vary is the number of matched strata:

**Factor 1:** Number of matched strata  $I$ : 100, 500, and 1000.

For each unit  $k$  in matched pair  $j$  within stratum  $i \in [I]$ , its principal stratum membership  $S_{ijk}$  is sampled from the following multinomial distribution:

$$P(S_{ijk} = \text{SW}) = p;$$

$$P(S_{ijk} \in \{\text{ACO}, \text{AT-NT}, \text{AAT}, \text{NT-AT}, \text{ANT}\}) = (1 - p)/5.$$

Recall switchers entail those who switch from a never-taker to a complier and from an always-taker to a complier. Half of switchers in our data-generating process are never-takers under a weaker IV, and the other half are always-takers. For each unit  $ijk$ , the potential outcomes  $\{d_{T^{a_{ijk}}}, d_{C^{a_{ijk}}}, d_{T^{b_{ijk}}}, d_{C^{b_{ijk}}}\}$  are determined by  $S_{ijk}$ .

The second factor we vary is the proportion of switchers:

**Factor 2:** Proportion of switchers  $p$ : 0.3, 0.5, and 0.7.

Next, we generate potential “per-protocol” outcomes  $\{r_{d=0,ijk}, r_{d=1,ijk}\}$  as follows:

$$r_{d=0,ijk} \sim \mathcal{N}(0, 1), \quad r_{d=1,ijk} = r_{d=0,ijk} + \tau_{ijk},$$

where the treatment effect  $\tau_{ijk}$  is heterogeneous and depends on  $ijk$ 's principal stratum membership:  $\tau_{ijk} \sim \mathcal{N}(0.5, 1)$  for always-compliers,  $\tau_{ijk} \sim \mathcal{N}(0.1, 1)$  for other non-switcher strata (AT-NT, AAT, NT-AT, or ANT), and  $\tau_{ijk}$  is drawn from one of the following distributions for switchers:

**Factor 3:** Treatment effect among switchers,  $\tau_{ijk}^{\text{SW}}$ , follows one of the three distributions:

- (i)  $\tau_{ijk}^{\text{SW}} \sim \text{Unif}[\mu - \sqrt{3}, \mu + \sqrt{3}]$ ; (ii)  $\tau_{ijk}^{\text{SW}} \sim \mathcal{N}(\mu, 1)$ ; and (iii)  $\tau_{ijk}^{\text{SW}} \sim \text{Exp}(1/\mu)$ .

In each distribution,  $\mu$  controls the magnitude of the effect size among switchers, which is varied as the fourth factor:

**Factor 4:** Effect size among switchers  $\mu$ : 0, 0.25, 0.5, and 1.

After we generate participant  $ijk$ 's principal stratum  $S_{ijk}$  and potential "per-protocol" outcomes  $\{r_{d=0,ijk}, r_{d=1,ijk}\}$ , potential outcomes  $\{r_{T^aijk}, r_{C^aijk}, r_{T^bijk}, r_{C^bijk}\}$  are then determined by  $\{r_{d=0,ijk}, r_{d=1,ijk}, S_{ijk}\}$ .

Finally, we generate IV assignment vector  $\mathbf{Z}_i = (Z_{i11}, Z_{i12}, Z_{i21}, Z_{i22})$  for each stratum  $i$  independently according to the randomization scheme in Assumption 1. For each unit  $ijk$ , the observed treatment received and outcome are determined as follows:

$$D_{ijk} = d_{C^aijk} \mathbb{I}\{Z_{ijk} = 0_a\} + d_{T^aijk} \mathbb{I}\{Z_{ijk} = 1_a\} + d_{C^bijk} \mathbb{I}\{Z_{ijk} = 0_b\} + d_{T^bijk} \mathbb{I}\{Z_{ijk} = 1_b\},$$

$$R_{ijk} = r_{d=1,ijk} \mathbb{I}\{D_{ijk} = 1\} + r_{d=0,ijk} \mathbb{I}\{D_{ijk} = 0\}.$$

To summarize, Factors 1-4 define 108 data-generating processes. For each DGP, we generated 1000 datasets and recorded the true sample average treatment effect  $\lambda_{\text{true}}$  among switchers in each dataset. We then evaluated the level and power of the randomization-based test in Theorem 2 by conducting two tests: (i)  $H_0 : \lambda = \lambda_{\text{true}}$  and (ii)  $H_0 : \lambda = 0$ . We also constructed confidence intervals for  $\lambda_{\text{true}}$  by inverting the test.

### 5.1.2 Simulation results

Table 2 summarizes the simulation results for different choices of the sample size  $I$ , switcher proportion  $p$ , and effect size  $\mu$ , when  $\tau_{ijk}^{\text{SW}} \sim \mathcal{N}(\mu, 1)$ . Reported metrics include type I error rate (level), empirical power, average length of the confidence intervals, and empirical

coverage of the 95% confidence intervals constructed according to Theorem 2. In addition, Table 2 reports the average compliance rate  $\bar{\ell}_g$  for each IV pair, the average true SW-SATE  $\bar{\lambda}_{\text{true}}$ , the average true standard deviation of the test statistic  $\text{SD}[T(\lambda_{\text{true}})]$  under  $\lambda = \lambda_{\text{true}}$ , and the average standard error estimator  $S(\lambda_{\text{true}})$ , all averaged over 1000 simulation replicates. Tables S2-S3 in the Supplemental Material B.1 summarize the same simulation results but for  $\tau_{ijk}^{\text{SW}} \sim \text{Unif}[\mu - \sqrt{3}, \mu + \sqrt{3}]$  and  $\tau_{ijk}^{\text{SW}} \sim \text{Exp}(1/\mu)$ .

We observed several consistent trends in the simulation studies. First, across all data-generating settings, the test maintained good type I error control, even with  $I$  as small as 100. The estimated standard errors slightly overestimated the true standard deviation, indicating that the variance estimator is mildly conservative. Second, as expected, the test's power increased and the confidence interval width decreased as the number of strata  $I$  grew and the proportion of switchers  $p$  became larger. For example, when the effect distribution among switchers follows a normal distribution with mean  $\mu = 1$ , the empirical power is 0.76 with a confidence interval width of 1.63 for  $I = 500$  strata and  $p = 0.3$ . Increasing the number of strata to  $I = 1000$  raised the empirical power to 0.96 and narrowed the confidence interval to 1.10. Further increasing the proportion of switchers to  $p = 0.7$  (with  $I = 1000$ ) yielded empirical power of 1.00 and reduced the interval width to 0.44. Third, fixing  $I$  and  $p$ , the test showed higher power with larger effect sizes. For instance, with  $I = 500$  and  $p = 0.3$ , when the effect distribution among switchers was uniform and the mean value increased from 0.25 to 1.0, empirical power rose from 0.11 to 0.74. Finally, the proposed method demonstrated robustness across a variety of effect size distributions.

In addition to the data-generating processes described in Section 5.1.1, we also examined the scenario discussed in Remark 4, where each stratum contains exactly two switchers, and the treatment effect among switchers is constant. We verified that the variance estimator  $S^2(\lambda_{\text{true}})$  is unbiased for the true variance under this setup; see Table S4 in Supplementary Material B.1 for details.

### 5.1.3 Hypothesis testing for the ACO-SATE

We also evaluated the validity and power of the hypothesis test for the ACO-SATE, constructed according to Theorem 1. The data-generating processes parallel those for SW-SATE in Section 5.1.1, except that the roles of switchers and always-compliers are swapped. For each simulated dataset, we computed the true sample average treatment effect  $\kappa_{\text{true}}$  for always-compliers and evaluated two hypothesis tests,  $H_0 : \kappa = \kappa_{\text{true}}$  and  $H_0 : \kappa = 0$ . We also constructed confidence intervals by inverting the test. Performance was assessed in terms of type I error, empirical power, confidence interval length, and coverage. Supplemental Material B.2.1 describes the simulation settings.

Tables S5–S7 in Supplemental Material B.2.2 report the simulation results, which closely parallel those for SW-SATE. First, the test maintains a type I error rate near the nominal level across all combinations of number of strata  $I$ , proportion of always-compliers  $p$ , and the effect size  $\mu$ . Even with  $I = 100$ , the coverage of the 95% confidence intervals stays close to the nominal level across all treatment effect distributions, demonstrating that the proposed randomization-based inference procedure performs reliably under finite samples and heterogeneous effect-size distributions. Second, increasing the number of strata  $I$  or the proportion of always-compliers  $p$  improves power and narrows confidence intervals. Finally, for fixed  $I$  and  $p$ , larger effect sizes  $\mu$  yield higher power, as expected.

## 5.2 Validity under a partly biased randomization scheme

We next evaluated the validity of Theorem 4 under a partly biased randomization scheme  $\mathcal{M}_\Gamma$ . Simulation results for Theorem 3 is analogous and omitted. We first simulated potential outcomes  $\{r_{T^{a_{ijk}}}, r_{C^{a_{ijk}}}, r_{T^{b_{ijk}}}, r_{C^{b_{ijk}}}\}$ , determined by  $\{r_{d=0,ijk}, r_{d=1,ijk}, S_{ijk}\}$ , following the data-generating process described in Section 5.1.1 with  $\tau_{ijk}^{\text{SW}} \sim \mathcal{N}(0, 1)$  and  $p = 0.5$ . The observed IV assignment vector  $\mathbf{Z}_i$  was then determined within each stratum in two steps. First, within each pair, two units were randomly assigned to treatment or control ( $0_g$  or  $1_g$  with  $g \in \{a, b\}$  to be determined). In the second step, we determined which pair received the stronger IV ( $0_b, 1_b$ ) and which received the weaker IV ( $0_a, 1_a$ ) as follows. Within each stratum we computed (1) the treated-minus-control transformed outcome dif-



ference under the IV pair  $(0_b, 1_b)$  in the first pair minus that under the IV pair  $(0_a, 1_a)$  in the second pair, and (2) the treated-minus-control transformed outcome difference under the IV pair  $(0_b, 1_b)$  in the second pair minus that under the IV pair  $(0_a, 1_a)$  in the first pair. The stronger IV pair  $(0_b, 1_b)$  was then assigned to the first pair with probability  $\pi_i$  if (1) exceeded (2), and to the second pair with probability  $\pi_i$  otherwise.

We considered two submodels of  $\mathcal{M}_\Gamma$ : (I)  $\pi_i \sim \text{Unif}\left[\frac{1}{2}, \frac{\Gamma}{\Gamma+1}\right]$ ; and (II)  $\pi_i = \frac{\Gamma}{\Gamma+1}$ . In addition, we considered three sample sizes:  $I = 100, 500$ , and  $1000$ , and we examined a range of  $\Gamma$  from  $\Gamma = 1.1$  to  $\Gamma = 2$ . For each simulation setting, we tested the null hypothesis  $H_0 : \lambda = \lambda_{\text{true}}$  at 0.05 level using randomization-based method (Theorem 2) or biased randomization-based method (Theorem 4). Table S8, Panel A in Supplemental Material B.3 reports the proportion of times the null hypothesis was rejected across 1000 simulated datasets, using inference based on Theorems 2 and 4, under a fixed  $\pi_i$  submodel,  $I$ , and  $\Gamma$ . Two key findings emerge. First, when data were generated under a partly biased randomization scheme, randomization inference for the SW-SATE using Theorem 2 exhibited inflated Type I error rates, with the degree of inflation increasing in  $\Gamma$  (i.e., as the maximum allowable bias grew). Second, inference based on Theorem 4 consistently controlled the Type I error rate at the nominal level. The resulting procedure is highly conservative under Submodel I, because the theorem is derived under the worst-case  $\mathcal{M}_\Gamma$ , whereas Submodel II does not reflect such worst-case scenarios. Under Submodel II, the inference based on Theorem 4 was only slightly conservative.

We next considered settings where the sensitivity analysis was less conservative. In a second set of simulations, we fixed compliance status across strata, with each stratum containing one pair of switchers and one pair of always-compliers. Baseline outcomes were generated as  $r_{d=0,ijk} \sim \mathcal{N}(0, 0.1^2)$ , and treatment effects were held constant within compliance subgroups:  $\tau_{ijk}^{\text{SW}} = 0$  for switchers and  $\tau_{ijk}^{\text{ACO}} = 0.5$  for always-compliers. Finally, we set  $\pi_i = \frac{\Gamma}{\Gamma+1}$ . Panel B of Table S8 summarizes the results. In this setup, hypothesis testing using Theorem 4 produced rejection rates closer to the nominal 5% level while maintaining statistical validity.

## 6 Revisiting the PLCO Study

Table 3 reports the number of confirmed colorectal cancer cases across the four matched groups in the PoP-NIV design: treatment and control groups before and after 1997. We estimated the always-complier sample average treatment effect based on the covariate-balanced design shown in Table 1. We estimated that 52.2% participants (95% CI: 50.4% to 53.9%) in the entire cohort were always-compliers. Applying Theorem 1, we obtained a 95% confidence interval for the ACO-SATE ranging from  $-1.90\%$  to  $0.65\%$ , with a point estimate of  $-0.62\%$ . This provides weak evidence that colorectal cancer screening reduced incidence among always-compliers.

Always-compliers—those who comply even under a weak incentive—may disproportionately represent individuals with stronger health-seeking behaviors or poorer baseline health. A natural next question is: what would be the broader public health impact if colorectal cancer screening were scaled up in such a way that more individuals participated? To address this, we estimated the sample average treatment effect among switchers—those induced into compliance by the stronger incentive—as  $1.46\%$  (95% CI:  $-1.97\%$  to  $4.91\%$ ), with switchers comprising  $26.7\%$  (95% CI:  $24.5\%$  to  $28.9\%$ ) of the study population.

This finding is qualitatively consistent with efficient influence function–based estimates in Wang et al. (2024) and aligns well with the raw data: while compliance rates improved after 1997, the intention-to-treat effect did not increase and may even have declined. Intuitively, this suggests that the additional compliers brought in by the stronger instrument derived little benefit, perhaps because their baseline colorectal cancer risk was already low.

Taken together, always-compliers and switchers constitute nearly 80% of the study cohort. The data provide no direct information about the treatment effect in the remaining study cohort, which includes mixtures of always-taker-never-takers (AT-NTs), always-taker-takers (AATs), never-taker-always-takers (NT-ATs), and always-never-takers (ANTs). If one is willing to impose further assumptions—for example, that the treatment effect in this group equals that among switchers—then it is possible to extrapolate and estimate the sample average treatment effect in the full cohort as  $0.37\%$  (95% CI:  $-2.55\%$

to 3.31%).

Table 3: Sample size, percentage of treatment uptake, and the number of confirmed colorectal cancer cases in the matched cohort.

	Prior to 1997 ( $G = a$ )		After 1997 ( $G = b$ )	
	Control arm	Treatment arm	Control arm	Treatment arm
Sample size	3071	3071	3071	3071
Treatment uptake (%)	0 (0.0)	1602 (52.2)	0 (0.0)	2422 (78.9)
Confirmed colorectal cancer (%)	61 (2.0)	51 (1.7)	45 (1.5)	47 (1.5)

## 7 Summary and discussion

A common but often implicit assumption in instrumental variable analyses is that the instrumental variable has only one single version. This assumption is embedded in Rubin’s Stable Unit Treatment Value Assumption and violated when the definition of the IV is not unique. For example, randomization to treatment versus control, or encouragement to adhere to an assigned treatment, may involve trial- or site-specific features. Such heterogeneity is evident in variation of compliance rates across clinical sites within the same multicentre trial or across different trials evaluating the same intervention. For instance, in a meta-analysis of epidural analgesia, Zhou et al. (2019) reported compliance rates ranging from less than 5% to more than 50% across 10 studies. In this article, together with Wang et al. (2024), we show that such violations of SUTVA can in fact create new opportunities: certain principal stratum effects become non-parametrically identifiable under a nested IV framework.

In contrast to Wang et al. (2024), we study design-based inference within a nested IV framework. A design-based approach eliminates the need to estimate nuisance functions and often achieves better finite-sample performance. Two distinctive features of this framework merit emphasis. First, inference is made possible by a novel design of observational data, the “pair-of-pairs” design. Second, the design-based perspective naturally accommodates examining violations of the no unmeasured confounding assumption at the site or trial level. To this end, we introduced a novel “hierarchical” partly biased randomization model, which may be of independent interest.

The set of compliers under the stronger IV pair  $(0_b, 1_b)$  is precisely the union of always-compliers and switchers. Their “combined” treatment effect can therefore be estimated using the standard IV approach applied to the stronger IV pair  $(0_b, 1_b)$ . What, then, does the nested IV framework add? A key advantage of a nested IV analysis is its ability to decompose the overall effect among strong-IV compliers into two distinct groups: always-compliers and switchers. This decomposition makes it possible to detect heterogeneity in treatment effects and, in particular, to uncover a meaningful gradient in effect size. For example, in the PLCO trial, a conventional analysis of compliers after 1997 might suggest that screening had only a negligible impact. The nested IV framework, however, offers a richer interpretation: the negligible overall effect reflects a modest but likely genuine benefit among always-compliers combined with essentially a null effect among switchers. This gradient—from a beneficial point estimate in always-compliers to a null effect in switchers—provides substantive insights that would be otherwise missed under a traditional IV analysis.

## Acknowledgment

We are grateful to all study participants of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. De-identified PLCO trial data can be requested via the National Cancer Institute Cancer Data Access System.

## References

- Angrist, J. D., Imbens, G. W., and Rubin, D. B. (1996). Identification of causal effects using instrumental variables. *Journal of the American Statistical Association*, 91(434):444–455.
- Angrist, J. D. and Krueger, A. B. (1991). Does compulsory school attendance affect schooling and earnings? *The Quarterly Journal of Economics*, 106(4):979–1014.
- Angrist, J. D. and Krueger, A. B. (2001). Instrumental variables and the search for identification: From supply and demand to natural experiments. *Journal of Economic Perspectives*, 15(4):69–85.
- Baiocchi, M., Small, D. S., Lorch, S., and Rosenbaum, P. R. (2010). Building a stronger

- instrument in an observational study of perinatal care for premature infants. *Journal of the American Statistical Association*, 105(492):1285–1296.
- Blackwell, M. and Pashley, N. E. (2023). Noncompliance and instrumental variables for 2 k factorial experiments. *Journal of the American Statistical Association*, 118(542):1102–1114.
- Bound, J., Jaeger, D. A., and Baker, R. M. (1995). Problems with instrumental variables estimation when the correlation between the instruments and the endogenous explanatory variable is weak. *Journal of the American Statistical Association*, 90(430):443–450.
- Branson, Z. (2020). Randomization tests to assess covariate balance when designing and analyzing matched datasets. *Observational Studies*, 7(2):1–36.
- Chen, Z., Cho, M. H., and Zhang, B. (2025). Manipulating an instrumental variable in an observational study of premature babies: Design, bounds, and inference. *Journal of the American Statistical Association*, (just-accepted):1–24.
- Fogarty, C. B. (2020). Studentized sensitivity analysis for the sample average treatment effect in paired observational studies. *Journal of the American Statistical Association*, 115(531):1518–1530.
- Fogarty, C. B., Lee, K., Kelz, R. R., and Keele, L. J. (2021). Biased encouragements and heterogeneous effects in an instrumental variable study of emergency general surgical outcomes. *Journal of the American Statistical Association*, 116(536):1625–1636.
- Guo, R., Yi, J., Zhang, J., and Zhang, N. (2025). Rationed fertility: Treatment effect heterogeneity in the child quantity–quality tradeoff. *Journal of Political Economy*.
- Hull, P. (2018). Isolateing: Identifying counterfactual-specific treatment effects with cross-stratum comparisons. *Available at SSRN 2705108*.
- Imai, K. (2008). Variance identification and efficiency analysis in randomized experiments under the matched-pair design. *Statistics in Medicine*, 27(24):4857–4873.
- Imbens, G. W. and Rosenbaum, P. R. (2005). Robust, accurate confidence intervals with a weak instrument: quarter of birth and education. *Journal of the Royal Statistical Society: Series A (Statistics in Society)*, 168(1):109–126.
- Kang, H., Peck, L., and Keele, L. (2018). Inference for instrumental variables: a randomization inference approach. *Journal of the Royal Statistical Society Series A: Statistics in Society*, 181(4):1231–1254.

- Karmakar, B., Small, D. S., and Rosenbaum, P. R. (2019). Using approximation algorithms to build evidence factors and related designs for observational studies. *Journal of Computational and Graphical Statistics*, 28(3):698–709.
- Li, X. and Ding, P. (2017). General forms of finite population central limit theorems with applications to causal inference. *Journal of the American Statistical Association*, 112:1759–1769.
- Marcus, P. M., Ogden, S. L., Gren, L. H., Childs, J. C., Pretzel, S. M., Lamerato, L. E., Walsh, K., Rozjabek, H. M., Mabie, J., Thomas, B., et al. (2014). Non-compliance with the initial screening exam visit in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Preventive Medicine*, 67:82–88.
- Neyman, J. S. (1923). On the application of probability theory to agricultural experiments. Essay on principles. Section 9. *Annals of Agricultural Sciences*, 10:1–51.
- Rosenbaum, P. R. (2002). *Observational Studies*. Springer.
- Rosenbaum, P. R. (2010). *Design of Observational Studies*, volume 10. Springer.
- Rubin, D. B. (1974). Estimating causal effects of treatments in randomized and nonrandomized studies. *Journal of Educational Psychology*, 66(5):688.
- Rubin, D. B. (1980). Randomization analysis of experimental data: The fisher randomization test comment. *Journal of the American Statistical Association*, 75(371):591–593.
- Rubin, D. B. (1986). Statistics and causal inference: Comment: Which ifs have causal answers. *Journal of the American Statistical Association*, 81(396):961–962.
- Small, D. S. and Rosenbaum, P. R. (2008). War and wages: the strength of instrumental variables and their sensitivity to unobserved biases. *Journal of the American Statistical Association*, 103(483):924–933.
- Stuart, E. A., Cole, S. R., Bradshaw, C. P., and Leaf, P. J. (2011). The use of propensity scores to assess the generalizability of results from randomized trials. *Journal of the Royal Statistical Society: Series A (Statistics in Society)*, 174(2):369–386.
- Swanson, S. A., Hernán, M. A., Miller, M., Robins, J. M., and Richardson, T. S. (2018). Partial identification of the average treatment effect using instrumental variables: review of methods for binary instruments, treatments, and outcomes. *Journal of the American Statistical Association*, 113(522):933–947.

- Wang, R., Zhao, Y.-Q., Dukes, O., and Zhang, B. (2024). Nested instrumental variables design: Switcher average treatment effect, identification, efficient estimation and generalizability. *arXiv preprint arXiv:2405.07102*.
- Zhang, B., Heng, S., MacKay, E. J., and Ye, T. (2022). Bridging preference-based instrumental variable studies and cluster-randomized encouragement experiments: Study design, noncompliance, and average cluster effect ratio. *Biometrics*, 78(4):1639–1650.
- Zhang, B., Small, D., Lasater, K., McHugh, M., Silber, J., and Rosenbaum, P. (2023). Matching one sample according to two criteria in observational studies. *Journal of the American Statistical Association*, 118(542):1140–1151.
- Zhou, J., Hodges, J. S., Suri, M. F. K., and Chu, H. (2019). A bayesian hierarchical model estimating cace in meta-analysis of randomized clinical trials with noncompliance. *Biometrics*, 75(3):978–987.

Table 2: Simulation results over 1000 replicates for varying strata sizes ( $I$ ), proportions of switchers ( $p$ ), and effect size among switchers ( $\mu$ ), under a normal distribution of treatment effects among switchers:  $\tau_{ijk}^{\text{SW}} \sim \mathcal{N}(\mu, 1)$ . Reported metrics include level, power, average compliance rate under the weaker IV pair ( $\bar{\tau}_a$ ), average compliance rate under the stronger IV pair ( $\bar{\tau}_b$ ), average SW-SATE ( $\bar{\lambda}_{\text{true}}$ ), average length of the confidence interval, coverage probability of the confidence interval (cov. (%)), the standard deviation of the test statistic under  $\lambda = \lambda_{\text{true}}$  ( $\text{SD}[\text{T}(\lambda_{\text{true}})]$ ), and the conservative standard error estimator ( $S(\lambda_{\text{true}})$ ).

$I$	$p$	$\mu$	level	power	$\bar{\tau}_a$	$\bar{\tau}_b$	$\bar{\lambda}_{\text{true}}$	CI		$100 \times \text{SD}[\text{T}(\lambda_{\text{true}})]$	$100 \times S(\lambda_{\text{true}})$
								length	cov.(%)		
100	0.30	0.00	0.05	0.05	0.14	0.44	0.00	4.96	95.2	6.11	6.13
100	0.30	0.25	0.05	0.07	0.14	0.44	0.25	4.92	94.8	6.11	6.13
100	0.30	0.50	0.06	0.10	0.14	0.44	0.50	4.88	93.7	6.14	6.16
100	0.30	1.00	0.05	0.21	0.14	0.44	1.00	5.01	94.8	6.41	6.44
100	0.50	0.00	0.05	0.05	0.10	0.60	0.00	2.21	94.7	6.09	6.14
100	0.50	0.25	0.06	0.08	0.10	0.60	0.25	2.23	93.5	6.09	6.12
100	0.50	0.50	0.05	0.18	0.10	0.60	0.50	2.25	94.0	6.12	6.18
100	0.50	1.00	0.04	0.52	0.10	0.60	1.00	2.33	95.1	6.31	6.37
100	0.70	0.00	0.04	0.04	0.06	0.76	0.00	1.45	95.3	6.04	6.12
100	0.70	0.25	0.04	0.11	0.06	0.76	0.25	1.44	95.6	6.04	6.13
100	0.70	0.50	0.06	0.30	0.06	0.76	0.50	1.44	94.4	6.07	6.14
100	0.70	1.00	0.06	0.80	0.06	0.76	1.00	1.48	93.1	6.22	6.30
500	0.30	0.00	0.04	0.05	0.14	0.44	0.00	1.54	95.1	2.74	2.75
500	0.30	0.25	0.05	0.10	0.14	0.44	0.25	1.55	95.1	2.73	2.75
500	0.30	0.50	0.04	0.27	0.14	0.44	0.50	1.57	95.7	2.76	2.77
500	0.30	1.00	0.04	0.76	0.14	0.44	1.00	1.63	95.7	2.86	2.88
500	0.50	0.00	0.03	0.04	0.10	0.60	0.00	0.87	96.0	2.72	2.75
500	0.50	0.25	0.04	0.21	0.10	0.60	0.25	0.87	95.5	2.72	2.74
500	0.50	0.50	0.05	0.61	0.10	0.60	0.50	0.87	93.7	2.73	2.76
500	0.50	1.00	0.05	0.99	0.10	0.60	1.00	0.91	94.7	2.83	2.86
500	0.70	0.00	0.04	0.04	0.06	0.76	0.00	0.61	95.5	2.70	2.74
500	0.70	0.25	0.04	0.38	0.06	0.76	0.25	0.61	94.6	2.70	2.74
500	0.70	0.50	0.04	0.89	0.06	0.76	0.50	0.61	95.4	2.71	2.75
500	0.70	1.00	0.05	1.00	0.06	0.76	1.00	0.63	94.0	2.78	2.82
1000	0.30	0.00	0.05	0.05	0.14	0.44	0.00	1.05	94.5	1.93	1.95
1000	0.30	0.25	0.04	0.17	0.14	0.44	0.25	1.04	96.0	1.93	1.94
1000	0.30	0.50	0.05	0.49	0.14	0.44	0.50	1.05	94.2	1.94	1.95
1000	0.30	1.00	0.05	0.96	0.14	0.44	1.00	1.10	94.5	2.03	2.04
1000	0.50	0.00	0.04	0.04	0.10	0.60	0.00	0.61	96.0	1.92	1.94
1000	0.50	0.25	0.04	0.35	0.10	0.60	0.25	0.60	94.8	1.92	1.94
1000	0.50	0.50	0.05	0.88	0.10	0.60	0.50	0.61	95.0	1.93	1.95
1000	0.50	1.00	0.06	1.00	0.10	0.60	1.00	0.63	94.4	2.00	2.02
1000	0.70	0.00	0.04	0.04	0.06	0.76	0.00	0.43	95.5	1.91	1.94
1000	0.70	0.25	0.05	0.60	0.06	0.76	0.25	0.43	94.9	1.91	1.94
1000	0.70	0.50	0.04	0.99	0.06	0.76	0.50	0.43	94.4	1.92	1.95
1000	0.70	1.00	0.06	1.00	0.06	0.76	1.00	0.44	94.2	1.97	1.99



# Supplemental Materials to “Design-based inference for switcher average treatment effect”

## Supplemental Material A: Proofs

### A.1 Regularity conditions and lemmas

Throughout the proofs, define for each unit  $ijk$  the adjusted outcomes under stage  $g \in \{a, b\}$ :

$$y_{T^gijk} = r_{T^gijk} - \lambda_0 d_{T^gijk}, \quad y_{C^gijk} = r_{C^gijk} - \lambda_0 d_{C^gijk}.$$

Define for each stratum  $i$  and treatment assignment realization

$$(t_1, t_2) \in \{(+1, +1), (+1, -1), (-1, +1), (-1, -1)\},$$

the quantities  $\eta_{i, \text{ACO}}^{(t_1, t_2)}$  and  $\eta_{i, \text{SW}}^{(t_1, t_2)}$  as follows:

$$\begin{aligned} \eta_{i, \text{ACO}}^{(1, -1)} &= \frac{1}{2} [(y_{T^a i 11} - y_{C^a i 12}) - (y_{T^a i 22} - y_{C^a i 21})], \\ \eta_{i, \text{ACO}}^{(-1, -1)} &= \frac{1}{2} [(y_{T^a i 12} - y_{C^a i 11}) - (y_{T^a i 22} - y_{C^a i 21})], \\ \eta_{i, \text{ACO}}^{(-1, 1)} &= \frac{1}{2} [(y_{T^a i 12} - y_{C^a i 11}) - (y_{T^a i 21} - y_{C^a i 22})], \\ \eta_{i, \text{ACO}}^{(1, 1)} &= \frac{1}{2} [(y_{T^a i 11} - y_{C^a i 12}) - (y_{T^a i 21} - y_{C^a i 22})]. \\ \eta_{i, \text{SW}}^{(1, -1)} &= \frac{1}{2} [(y_{T^a i 22} - y_{C^a i 21}) + (y_{T^b i 22} - y_{C^b i 21})] - \frac{1}{2} [(y_{T^a i 11} - y_{C^a i 12}) + (y_{T^b i 11} - y_{C^b i 12})], \\ \eta_{i, \text{SW}}^{(-1, -1)} &= \frac{1}{2} [(y_{T^a i 22} - y_{C^a i 21}) + (y_{T^b i 22} - y_{C^b i 21})] - \frac{1}{2} [(y_{T^a i 12} - y_{C^a i 11}) + (y_{T^b i 12} - y_{C^b i 11})], \\ \eta_{i, \text{SW}}^{(-1, 1)} &= \frac{1}{2} [(y_{T^a i 21} - y_{C^a i 22}) + (y_{T^b i 21} - y_{C^b i 22})] - \frac{1}{2} [(y_{T^a i 12} - y_{C^a i 11}) + (y_{T^b i 12} - y_{C^b i 11})], \\ \eta_{i, \text{SW}}^{(1, 1)} &= \frac{1}{2} [(y_{T^a i 21} - y_{C^a i 22}) + (y_{T^b i 21} - y_{C^b i 22})] - \frac{1}{2} [(y_{T^a i 11} - y_{C^a i 12}) + (y_{T^b i 11} - y_{C^b i 12})]. \end{aligned}$$

All results are established conditional upon the set of potential outcomes  $\mathcal{F}$  and the set of possible IV configurations  $\mathcal{Z}$ .

**Condition 1.** For  $j, k \in \{1, 2\}$ , there exist constants  $\mu_{T^a jk}$ ,  $\mu_{C^a jk}$ ,  $\mu_{T^b jk}$  and  $\mu_{C^b jk}$  such that

$$\begin{aligned} \lim_{I \rightarrow \infty} I^{-1} \sum_{i=1}^I y_{T^a ijk} &= \mu_{T^a jk}, & \lim_{I \rightarrow \infty} I^{-1} \sum_{i=1}^I y_{C^a ijk} &= \mu_{C^a jk}, \\ \lim_{I \rightarrow \infty} I^{-1} \sum_{i=1}^I y_{T^b ijk} &= \mu_{T^b jk}, & \lim_{I \rightarrow \infty} I^{-1} \sum_{i=1}^I y_{C^b ijk} &= \mu_{C^b jk}, \\ \lim_{I \rightarrow \infty} I^{-2} \sum_{i=1}^I y_{T^a ijk}^2 &= 0, & \lim_{I \rightarrow \infty} I^{-2} \sum_{i=1}^I y_{C^a ijk}^2 &= 0, & \lim_{I \rightarrow \infty} I^{-2} \sum_{i=1}^I y_{T^b ijk}^2 &= 0, & \lim_{I \rightarrow \infty} I^{-2} \sum_{i=1}^I y_{C^b ijk}^2 &= 0, \end{aligned}$$

$$\lim_{I \rightarrow \infty} I^{-2} \sum_{i=1}^I y_{T^a ijk}^4 = 0, \quad \lim_{I \rightarrow \infty} I^{-2} \sum_{i=1}^I y_{C^a ijk}^4 = 0, \quad \lim_{I \rightarrow \infty} I^{-2} \sum_{i=1}^I y_{T^b ijk}^4 = 0, \quad \lim_{I \rightarrow \infty} I^{-2} \sum_{i=1}^I y_{C^b ijk}^4 = 0$$

**Condition 2.** *There exists a constant  $C > 0$  such that*

$$\lim_{I \rightarrow \infty} \frac{1}{I} \sum_{i=1}^I \text{Var}(V_i) > C, \quad \lim_{I \rightarrow \infty} \frac{1}{I} \sum_{i=1}^I \text{Var}(V_{i,\text{ACO}}(\kappa_0)) > C, \quad \lim_{I \rightarrow \infty} \frac{1}{I} \sum_{i=1}^I \text{Var}(V_{i,\text{SW}}(\lambda_0)) > C.$$

**Condition 3.** *There exists a constant  $C > 0$  such that*

$$\lim_{I \rightarrow \infty} \frac{1}{I} \sum_{i=1}^I \sum_{t_1 \in \{1, -1\}} \sum_{t_2 \in \{1, -1\}} \left( \eta_{i,\text{ACO}}^{(t_1, t_2)} \right)^2 > C,$$

and

$$\lim_{I \rightarrow \infty} \frac{1}{I} \sum_{i=1}^I \sum_{t_1 \in \{1, -1\}} \sum_{t_2 \in \{1, -1\}} \left( \eta_{i,\text{SW}}^{(t_1, t_2)} \right)^2 > C,$$

**Lemma 1** (Conservative Variance Estimation). *For independent random variables  $X_1, \dots, X_I$ , the expectation of the sample variance divided further by  $I$  provides a conservative estimate of the variance of the sample mean:*

$$\mathbb{E} \left[ \frac{1}{I(I-1)} \sum_{i=1}^I (X_i - \bar{X})^2 \right] \geq \text{Var}(\bar{X})$$

with equality if and only if  $E(X_i)$  is constant across all  $i$ .

*Proof.* We decompose the expectation of the sample variance as follows:

$$\begin{aligned} \mathbb{E} \left[ \sum_{i=1}^I (X_i - \bar{X})^2 \right] &= \mathbb{E} \left[ \sum_{i=1}^I X_i^2 \right] - I \mathbb{E} [\bar{X}^2] \\ &= \sum_{i=1}^I [\text{Var}(X_i) + \mathbb{E}^2(X_i)] - I [\text{Var}(\bar{X}) + \mathbb{E}^2(\bar{X})] \\ &= \sum_{i=1}^I \text{Var}(X_i) - I \text{Var}(\bar{X}) + \sum_{i=1}^I \mathbb{E}^2(X_i) - I \mathbb{E}^2(\bar{X}) \\ &= I^2 \text{Var}(\bar{X}) - I \text{Var}(\bar{X}) + \sum_{i=1}^I [\mathbb{E}(X_i) - \mathbb{E}(\bar{X})]^2 \\ &= I(I-1) \text{Var}(\bar{X}) + \sum_{i=1}^I [\mathbb{E}(X_i) - \mathbb{E}(\bar{X})]^2 \end{aligned}$$

Therefore,

$$\mathbb{E} \left[ \frac{1}{I(I-1)} \sum_{i=1}^I (X_i - \bar{X})^2 \right] = \text{Var}(\bar{X}) + \frac{1}{I(I-1)} \sum_{i=1}^I [\mathbb{E}(X_i) - \mathbb{E}(\bar{X})]^2 \geq \text{Var}(\bar{X}),$$

where equality holds if and only if  $\mathbb{E}(X_i)$  is constant for all  $i$ .  $\square$

**Lemma 2.** Let  $D_1, \dots, D_I$  be independent random variables with means  $\mu_i = \mathbb{E}(D_i)$  and variances  $\sigma_i^2 = \text{Var}(D_i)$ . Assume there exists a constant  $c > 0$  and that as  $I \rightarrow \infty$ :

$$(i) \text{ (Nondegeneracy) } I^{-1} \sum_{i=1}^I \sigma_i^2 \geq c.$$

$$(ii) \text{ (Fourth-moment vanishing) } I^{-2} \sum_{i=1}^I \mathbb{E}(D_i^4) \rightarrow 0.$$

Then, writing  $\bar{D}_I = I^{-1} \sum_{i=1}^I D_i$ , we have

$$\frac{\sqrt{I}\bar{D}_I - \mathbb{E}(\sqrt{I}\bar{D}_I)}{\sqrt{\text{var}(\sqrt{I}\bar{D}_I)}} \xrightarrow{d} \mathcal{N}(0, 1), \quad \text{as } I \rightarrow \infty.$$

*Proof.* For any real numbers  $x$  and  $\mu$ , the elementary inequality  $|x - \mu|^4 \leq 8(x^4 + \mu^4)$  holds. Applying this to  $D_i$  and taking expectations gives

$$\mathbb{E}|D_i - \mu_i|^4 \leq 8\{\mathbb{E}(D_i^4) + \mu_i^4\}.$$

Since the function  $f(x) = x^4$  is convex on  $\mathbb{R}$ , Jensen's inequality yields

$$\mu_i^4 = f(\mathbb{E}[D_i]) \leq \mathbb{E}(f(D_i)) = \mathbb{E}(D_i^4).$$

Hence  $\mathbb{E}|D_i - \mu_i|^4 \leq 8\{\mathbb{E}(D_i^4) + \mathbb{E}(D_i^4)\} = 16 \mathbb{E}(D_i^4)$ . It follows that

$$\sum_{i=1}^I \mathbb{E}|I^{-1/2}D_i - I^{-1/2}\mu_i|^4 = I^{-2} \sum_{i=1}^I \mathbb{E}|D_i - \mu_i|^4 \leq 16I^{-2} \sum_{i=1}^I \mathbb{E}(D_i^4).$$

By assumption (i),

$$\sum_{i=1}^I \text{Var}(I^{-1/2}D_i) = I^{-1} \sum_{i=1}^I \sigma_i^2 \geq c.$$

Therefore,

$$\frac{\sum_{i=1}^I \mathbb{E}|I^{-1/2}D_i - I^{-1/2}\mu_i|^4}{\left(\sum_{i=1}^I \text{Var}(I^{-1/2}D_i)\right)^2} \leq \frac{16}{c^2} I^{-2} \sum_{i=1}^I \mathbb{E}(D_i^4).$$

By assumption (ii), the right-hand side tends to 0 as  $I \rightarrow \infty$ . Hence, the Lyapunov condition with exponent 4 holds, and Lyapunov's central limit theorem implies

$$\frac{\sum_{i=1}^I (I^{-1/2} D_i - I^{-1/2} \mu_i)}{\sqrt{\sum_{i=1}^I \text{Var}(I^{-1/2} D_i)}} \xrightarrow{d} \mathcal{N}(0, 1),$$

which is equivalent to the stated result by the identity

$$\sum_{i=1}^I (I^{-1/2} D_i - I^{-1/2} \mu_i) = \sqrt{I} (\bar{D}_I - \mathbb{E}[\bar{D}_I]) \quad \text{and} \quad \sum_{i=1}^I \text{Var}(I^{-1/2} D_i) = \text{Var}(\sqrt{I} \bar{D}_I).$$

□

**Lemma 3.** *Let  $\{D_i\}_{i=1}^I$  be independent random variables, and define*

$$\bar{D}_I = \frac{1}{I} \sum_{i=1}^I D_i, \quad S^2 = \frac{1}{I(I-1)} \sum_{i=1}^I (D_i - \bar{D}_I)^2.$$

*Suppose that, as  $I \rightarrow \infty$ ,*

- (i)  $\mathbb{E}(\bar{D}_I) = O(1)$ ;*
- (ii)  $I^{-2} \sum_{i=1}^I \mathbb{E}(D_i^2) \rightarrow 0$ ;*
- (iii)  $I^{-2} \sum_{i=1}^I \mathbb{E}(D_i^4) \rightarrow 0$ .*

*Then  $IS^2 - I \mathbb{E}(S^2)$  converges in probability to 0.*

*Proof.* Recall that

$$IS^2 = \frac{1}{I-1} \sum_{i=1}^I (D_i - \bar{D}_I)^2 = \frac{1}{I-1} \sum_{i=1}^I D_i^2 - \frac{I}{I-1} \bar{D}_I^2.$$

By the fourth-moment condition (iii) and independence,

$$\text{Var} \left( \frac{1}{I-1} \sum_{i=1}^I D_i^2 \right) \leq \frac{1}{(I-1)^2} \sum_{i=1}^I \mathbb{E}(D_i^4) \rightarrow 0.$$

Hence, by Chebyshev's inequality,

$$\frac{1}{I-1} \sum_{i=1}^I D_i^2 - \mathbb{E} \left[ \frac{1}{I-1} \sum_{i=1}^I D_i^2 \right] \xrightarrow{p} 0.$$

By condition (ii),

$$\text{Var}(\bar{D}_I) = I^{-2} \sum_{i=1}^I \text{Var}(D_i) \leq I^{-2} \sum_{i=1}^I \mathbb{E}(D_i^2) \rightarrow 0,$$

Chebyshev's inequality then implies that  $\bar{D}_I - \mathbb{E}(\bar{D}_I) \xrightarrow{p} 0$ , and thus  $(\bar{D}_I - \mathbb{E}\bar{D}_I)^2 \xrightarrow{p} 0$ . Noting that

$$\frac{I}{I-1} \bar{D}_I^2 - \frac{I}{I-1} \{\mathbb{E}(\bar{D}_I)\}^2 = \frac{I}{I-1} (\bar{D}_I - \mathbb{E}\bar{D}_I)^2 + \frac{2I}{I-1} \mathbb{E}(\bar{D}_I) (\bar{D}_I - \mathbb{E}\bar{D}_I),$$

where  $\mathbb{E}(\bar{D}_I) = O(1)$ , both terms converge in probability to 0. Therefore,

$$\frac{I}{I-1} \bar{D}_I^2 - \frac{I}{I-1} \{\mathbb{E}(\bar{D}_I)\}^2 \xrightarrow{p} 0.$$

Since  $\text{Var}(\bar{D}_I) = \mathbb{E}(\bar{D}_I^2) - \{\mathbb{E}(\bar{D}_I)\}^2$  converges to 0 as  $I \rightarrow \infty$ , it follows that

$$\frac{I}{I-1} \bar{D}_I^2 - \frac{I}{I-1} \mathbb{E}(\bar{D}_I^2) \xrightarrow{p} 0.$$

Put together, the above results imply that

$$IS^2 - I\mathbb{E}(S^2) \xrightarrow{p} 0.$$

□

## A.2 Proof of Proposition 2

*Proof.* Under the randomization mechanism in Assumption 1, each IV assignment vector  $\mathbf{Z}_i$  has equal probability among eight possible configurations. The full list of configurations and their induced  $(\mathbf{Z}_i^a, \mathbf{Z}_i^b)$  values are summarized in Table S1.

Table S1: IV dose assignment configurations

$\mathbf{Z}_i$	$(Z_{i11}^a, Z_{i12}^a, Z_{i21}^a, Z_{i22}^a)$	$(Z_{i11}^b, Z_{i12}^b, Z_{i21}^b, Z_{i22}^b)$
$(1_a, 0_a, 1_b, 0_b)$	$(1, 0, \frac{1}{2}, \frac{1}{2})$	$(\frac{1}{2}, \frac{1}{2}, 1, 0)$
$(0_a, 1_a, 1_b, 0_b)$	$(0, 1, \frac{1}{2}, \frac{1}{2})$	$(\frac{1}{2}, \frac{1}{2}, 1, 0)$
$(1_a, 0_a, 0_b, 1_b)$	$(1, 0, \frac{1}{2}, \frac{1}{2})$	$(\frac{1}{2}, \frac{1}{2}, 0, 1)$
$(0_a, 1_a, 0_b, 1_b)$	$(0, 1, \frac{1}{2}, \frac{1}{2})$	$(\frac{1}{2}, \frac{1}{2}, 0, 1)$
$(1_b, 0_b, 1_a, 0_a)$	$(\frac{1}{2}, \frac{1}{2}, 1, 0)$	$(1, 0, \frac{1}{2}, \frac{1}{2})$
$(1_b, 0_b, 0_a, 1_a)$	$(\frac{1}{2}, \frac{1}{2}, 0, 1)$	$(1, 0, \frac{1}{2}, \frac{1}{2})$
$(0_b, 1_b, 1_a, 0_a)$	$(\frac{1}{2}, \frac{1}{2}, 1, 0)$	$(0, 1, \frac{1}{2}, \frac{1}{2})$
$(0_b, 1_b, 0_a, 1_a)$	$(\frac{1}{2}, \frac{1}{2}, 0, 1)$	$(0, 1, \frac{1}{2}, \frac{1}{2})$

Taking the expectation conditional on the potential outcomes  $\mathcal{F}$ , we have

$$\begin{aligned}
\mathbb{E}[V_i \mid \mathcal{F}] &= \mathbb{E}\left\{\sum_{j=1}^2 \sum_{k=1}^2 \{Z_{ijk}^b D_{ijk} - (1 - Z_{ijk}^b) D_{ijk}\} - \{Z_{ijk}^a D_{ijk} - (1 - Z_{ijk}^a) D_{ijk}\} \mid \mathcal{F}\right\} \\
&= \frac{1}{8} \{(d_{T^b i 11} - d_{C^b i 12}) - (d_{T^a i 21} - d_{C^a i 22}) + (d_{T^b i 12} - d_{C^b i 11}) - (d_{T^a i 21} - d_{C^a i 22})\} \\
&\quad + \frac{1}{8} \{(d_{T^b i 11} - d_{C^b i 12}) - (d_{T^a i 22} - d_{C^a i 21}) + (d_{T^b i 12} - d_{C^b i 11}) - (d_{T^a i 22} - d_{C^a i 21})\} \\
&\quad + \frac{1}{8} \{(d_{T^b i 21} - d_{C^b i 22}) - (d_{T^a i 11} - d_{C^a i 12}) + (d_{T^b i 22} - d_{C^b i 21}) - (d_{T^a i 11} - d_{C^a i 12})\} \\
&\quad + \frac{1}{8} \{(d_{T^b i 21} - d_{C^b i 22}) - (d_{T^a i 12} - d_{C^a i 11}) + (d_{T^b i 22} - d_{C^b i 21}) - (d_{T^a i 12} - d_{C^a i 11})\} \\
&= \frac{1}{4} \sum_{j=1}^2 \sum_{k=1}^2 \{(d_{T^b i j k} - d_{C^b i j k}) - (d_{T^a i j k} - d_{C^a i j k})\}.
\end{aligned}$$

Define  $\bar{V} = \frac{1}{I} \sum_{i=1}^I V_i$ . By the definitions of  $\iota_b$  and  $\iota_a$ , it follows that

$$\mathbb{E}[\bar{V} \mid \mathcal{F}] = \frac{1}{4I} \sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 \{(d_{T^b i j k} - d_{C^b i j k}) - (d_{T^a i j k} - d_{C^a i j k})\} = \iota_b - \iota_a. \quad (8)$$

By construction, each  $V_i$  is a finite linear combination of potential outcomes  $d_{T^b i j k}, d_{C^b i j k}, d_{T^a i j k}, d_{C^a i j k}$ , all of which are binary. Hence, both  $\mathbb{E}[V_i]$  and  $\mathbb{E}[\bar{V}]$  are uniformly bounded, satisfying  $\mathbb{E}(\bar{V}) = O(1)$ . Moreover, since  $|V_i| < C$  for some universal constant  $C > 0$ , we have

$$I^{-2} \sum_{i=1}^I \mathbb{E}(V_i^2) \leq \frac{C^2}{I} \rightarrow 0, \quad I^{-2} \sum_{i=1}^I \mathbb{E}(V_i^4) \leq \frac{C^4}{I} \rightarrow 0.$$

Therefore, all conditions of Lemma 3 are satisfied, and  $IS^2 - I\mathbb{E}(S^2) \xrightarrow{p} 0$ . Moreover, by Lemma 1, the sample variance  $S^2 = \frac{1}{I(I-1)} \sum_{i=1}^I (V_i - \bar{V})^2$  satisfies  $\mathbb{E}[S^2] \geq \text{Var}(\bar{V})$ , which implies that

$$IS^2 - I\text{Var}(\bar{V}) - c_I \xrightarrow{p} 0, \quad (9)$$

where  $c_I = I\mathbb{E}[S^2] - I\text{Var}(\bar{V}) \geq 0$ .

From the regularity condition 2, we have  $\lim_{I \rightarrow \infty} \frac{1}{I} \sum_{i=1}^I \text{Var}(V_i) > c_0 > 0$  for some constant  $c_0$ . Since the  $V_i$  are independent across strata with bounded fourth moments, Lemma 2 yields

$$\frac{\sqrt{I}\bar{V} - \mathbb{E}(\sqrt{I}\bar{V})}{\sqrt{\text{Var}(\sqrt{I}\bar{V})}} \xrightarrow{d} \mathcal{N}(0, 1) \quad \text{as } I \rightarrow \infty.$$

Therefore, combining with (8) and (9), and under the null hypothesis  $H_{0, \text{nested IV}} : \iota_b - \iota_a = c$ ,

we have

$$\lim_{I \rightarrow \infty} \Pr\{|\sqrt{I}\bar{V} - \sqrt{I}c| \leq z_{1-\alpha/2}\sqrt{IS^2}\} \geq 1 - \alpha.$$

Equivalently, the interval

$$\{c : |\bar{V} - c| \leq z_{1-\alpha/2}\sqrt{S^2}\}$$

is an asymptotically valid  $(1 - \alpha)$  confidence interval for  $\iota_b - \iota_a$ .

□

### A.3 Proof of Theorem 1

*Proof.* Define the adjusted outcomes with  $\kappa_0$  under stage  $a$ :

$$y_{T^aijk} = r_{T^aijk} - \kappa_0 d_{T^aijk}, \quad y_{C^aijk} = r_{C^aijk} - \kappa_0 d_{C^aijk}$$

The test statistic can be expressed as:

$$\begin{aligned} V_{i,\text{ACO}}(\kappa_0) &= \sum_{j=1}^2 \sum_{k=1}^2 \{Z_{ijk}^a(R_{ijk} - \kappa_0 D_{ijk}) - (1 - Z_{ijk}^a)(R_{ijk} - \kappa_0 D_{ijk})\} \\ &= \sum_{j=1}^2 |2Z_{ij1}^a - 1| \sum_{k=1}^2 \{Z_{ijk}^a(R_{ijk} - \kappa_0 D_{ijk}) - (1 - Z_{ijk}^a)(R_{ijk} - \kappa_0 D_{ijk})\} \quad (10) \\ &= \sum_{j=1}^2 |2Z_{ij1}^a - 1| \sum_{k=1}^2 \{Z_{ijk}^a y_{T^aijk} - (1 - Z_{ijk}^a) y_{C^aijk}\} \\ &= \sum_{j=1}^2 |2Z_{ij1}^a - 1| \{Z_{ij1}^a (y_{T^aij1} - y_{C^aij2}) + (1 - Z_{ij1}^a) (y_{T^aij2} - y_{C^aij1})\} \end{aligned}$$

where (10) leverages the fact that  $|2Z_{ij1}^a - 1| = 1$  when pair  $ij$  is assigned to stage  $a$ , and 0 otherwise, which ensures that only pairs in stage  $a$  contribute to the sum.

Under the randomization probabilities in Table S1, for each matched pair  $ij$ , we have

$$\mathbb{E}[|2Z_{ij1}^a - 1| | Z_{ij1}^a] = \mathbb{P}(Z_{ij1}^a = 1) = \frac{1}{4}, \quad \mathbb{E}[|2Z_{ij1}^a - 1| (1 - Z_{ij1}^a)] = \mathbb{P}(Z_{ij1}^a = 0) = \frac{1}{4}.$$

Hence, under Condition 1,

$$\begin{aligned}
\mathbb{E}[T_{\text{ACO}}(\kappa_0) \mid \mathcal{F}] &= \frac{1}{I} \sum_{i=1}^I \mathbb{E}[V_{i,\text{ACO}}(\kappa_0) \mid \mathcal{F}] \\
&= \frac{1}{I} \sum_{i=1}^I \sum_{j=1}^2 \frac{1}{4} \{ (y_{T^{a_{ij}1}} - y_{C^{a_{ij}2}}) + (y_{T^{a_{ij}2}} - y_{C^{a_{ij}1}}) \} \\
&= \frac{1}{4I} \sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 (y_{T^{a_{ijk}}} - y_{C^{a_{ijk}}}) = O(1).
\end{aligned} \tag{11}$$

Under the null hypothesis  $H_0^{\text{ACO}} : \kappa = \kappa_0$ , we have

$$\begin{aligned}
\sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 (y_{T^{a_{ijk}}} - y_{C^{a_{ijk}}}) &= \sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 \{ (r_{T^{a_{ijk}}} - \kappa_0 d_{T^{a_{ijk}}}) - (r_{C^{a_{ijk}}} - \kappa_0 d_{C^{a_{ijk}}}) \} \\
&= \sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 \{ (r_{T^{a_{ijk}}} - r_{C^{a_{ijk}}}) - \kappa (d_{T^{a_{ijk}}} - d_{C^{a_{ijk}}}) \} \\
&= 0,
\end{aligned}$$

where the last equality follows from the definition of  $\kappa$ . Therefore,  $\mathbb{E}[T_{\text{ACO}}(\kappa_0) \mid \mathcal{F}] = 0$  under  $H_0^{\text{ACO}}$ .

By the Cauchy–Schwarz inequality,

$$\begin{aligned}
\frac{1}{I^2} \sum_{i=1}^I \mathbb{E}[V_{i,\text{ACO}}^2(\kappa_0) \mid \mathcal{F}] &= \frac{1}{I^2} \sum_{i=1}^I \frac{1}{4} \sum_{j=1}^2 \{ (y_{T^{a_{ij}1}} - y_{C^{a_{ij}2}})^2 + (y_{T^{a_{ij}2}} - y_{C^{a_{ij}1}})^2 \} \\
&\leq \frac{1}{2I^2} \sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 (y_{T^{a_{ijk}}}^2 + y_{C^{a_{ijk}}}^2),
\end{aligned} \tag{12}$$

which converges to 0 as  $I \rightarrow \infty$  under Condition 1.

Similarly, by Hölder’s inequality,

$$\begin{aligned}
\frac{1}{I^2} \sum_{i=1}^I \mathbb{E}[V_{i,\text{ACO}}^4(\kappa_0) \mid \mathcal{F}] &= \frac{1}{I^2} \sum_{i=1}^I \frac{1}{4} \sum_{j=1}^2 \{ (y_{T^{a_{ij}1}} - y_{C^{a_{ij}2}})^4 + (y_{T^{a_{ij}2}} - y_{C^{a_{ij}1}})^4 \} \\
&\leq \frac{1}{4I^2} \sum_{i=1}^I \sum_{j=1}^2 8 \sum_{k=1}^2 (y_{T^{a_{ijk}}}^4 + y_{C^{a_{ijk}}}^4),
\end{aligned} \tag{13}$$

which also converges to 0 under Condition 1.



Thus, under  $H_0^{\text{ACO}}$  and Conditions 1-2, we apply Lemma 2 to  $V_{i,\text{ACO}}(\kappa_0)$  and conclude:

$$\frac{\sqrt{I}T_{\text{ACO}}(\kappa_0)}{\sqrt{\text{Var}(\sqrt{I}T_{\text{ACO}}(\kappa_0))}} \xrightarrow{d} \mathcal{N}(0, 1), \quad \text{as } I \rightarrow \infty.$$

It remains to show that  $IS_{\text{ACO}}^2(\kappa_0)$  is a conservative estimator of  $\text{Var}(\sqrt{I}T_{\text{ACO}}(\kappa_0))$ . Decompose

$$IS_{\text{ACO}}^2(\kappa_0) - I\text{Var}(T_{\text{ACO}}(\kappa_0)) = (IS_{\text{ACO}}^2(\kappa_0) - IE[S_{\text{ACO}}^2(\kappa_0)]) + (IE[S_{\text{ACO}}^2(\kappa_0)] - I\text{Var}(T_{\text{ACO}}(\kappa_0))).$$

By Lemma 3 and the bounded-moment results in (11)–(13), the first term converges in probability to 0, while the second is nonnegative by Lemma 1. Therefore,

$$IS_{\text{ACO}}^2(\kappa_0) - \text{Var}(\sqrt{I}T_{\text{ACO}}(\kappa_0)) - c_I \xrightarrow{p} 0,$$

where  $c_I = IE[S_{\text{ACO}}^2(\kappa_0)] - I\text{Var}(T_{\text{ACO}}(\kappa_0)) \geq 0$ . This establishes that confidence intervals based on  $IS_{\text{ACO}}^2(\kappa_0)$  are asymptotically valid and conservative.

Note that

$$\begin{aligned} E[V_{i,\text{ACO}}(\kappa_0) \mid \mathcal{F}] &= \frac{1}{4} \sum_{j=1}^2 \sum_{k=1}^2 \{y_{T^{a_{ijk}}} - y_{C^{a_{ijk}}}\} \\ &= \frac{1}{4} \sum_{j=1}^2 \sum_{k=1}^2 \{r_{T^{a_{ijk}}} - r_{C^{a_{ijk}}} - \kappa_0(d_{T^{a_{ijk}}} - d_{C^{a_{ijk}}})\}. \end{aligned}$$

For the non-always-complier units who are always-takers or never-takers under the IV pair  $(0_a, 1_a)$ , we have  $r_{T^{a_{ijk}}} - r_{C^{a_{ijk}}} = d_{T^{a_{ijk}}} - d_{C^{a_{ijk}}} = 0$ , and therefore

$$\begin{aligned} E[V_{i,\text{ACO}}(\kappa_0) \mid \mathcal{F}] &= \frac{1}{4} \sum_{j=1}^2 \sum_{k=1}^2 \{r_{T^{a_{ijk}}} - r_{C^{a_{ijk}}} - \kappa_0(d_{T^{a_{ijk}}} - d_{C^{a_{ijk}}})\} \mathbb{I}(S_{ijk} = \text{ACO}) \\ &= \frac{1}{4} \sum_{j=1}^2 \sum_{k=1}^2 \{r_{d=1,ijk} - r_{d=0,ijk} - \kappa_0\} \mathbb{I}(S_{ijk} = \text{ACO}). \end{aligned}$$

Finally,  $IS_{\text{ACO}}^2(\kappa_0)$  is unbiased for  $\text{Var}(\sqrt{I}T_{\text{ACO}}(\kappa_0))$  if and only if

$$E[V_{i,\text{ACO}}(\kappa_0) \mid \mathcal{F}] = \frac{1}{4} \sum_{j=1}^2 \sum_{k=1}^2 \{r_{d=1,ijk} - r_{d=0,ijk} - \kappa_0\} \mathbb{I}(S_{ijk} = \text{ACO})$$

is constant across all  $i = 1, \dots, I$ . A sufficient condition for this to hold is that the treatment

effect among always-compliers is constant, i.e.,

$$r_{d=1,ijk} - r_{d=0,ijk} = \kappa \quad \text{for all always-compliers.}$$

Under  $H_0^{\text{ACO}} : \kappa = \kappa_0$ , this implies  $E[V_{i,\text{ACO}}(\kappa_0) \mid \mathcal{F}] = 0$  for all  $i$ .

□

## A.2 Proof of Theorem 2

*Proof.* By the same logic as in the proof of Theorem 1,

$$\begin{aligned} V_{i,\text{SW}}(\lambda_0) &= \sum_{j=1}^2 |2Z_{ij1}^b - 1| \{Z_{ij1}^b (y_{T^b_{ij1}} - y_{C^b_{ij2}}) + (1 - Z_{ij1}^b) (y_{T^b_{ij2}} - y_{C^b_{ij1}})\} \\ &\quad - \sum_{j=1}^2 |2Z_{ij1}^a - 1| \{Z_{ij1}^a (y_{T^a_{ij1}} - y_{C^a_{ij2}}) + (1 - Z_{ij1}^a) (y_{T^a_{ij2}} - y_{C^a_{ij1}})\} \end{aligned}$$

Under the equal probabilities of assignment in Table S1, the conditional expectation of  $V_{i,\text{SW}}(\lambda_0)$  given  $\mathcal{F}$  is

$$E[V_{i,\text{SW}}(\lambda_0) \mid \mathcal{F}] = \frac{1}{4} \sum_{j=1}^2 \sum_{k=1}^2 \{(y_{T^b_{ijk}} - y_{C^b_{ijk}}) - (y_{T^a_{ijk}} - y_{C^a_{ijk}})\}.$$

Taking the average across strata, we then obtain

$$\begin{aligned} E[T_{\text{SW}}(\lambda_0) \mid \mathcal{F}] &= \frac{1}{I} \sum_{i=1}^I E[V_{i,\text{SW}}(\lambda_0) \mid \mathcal{F}] \\ &= \frac{1}{4I} \sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 \{(y_{T^b_{ijk}} - y_{C^b_{ijk}}) - (y_{T^a_{ijk}} - y_{C^a_{ijk}})\} \\ &= \frac{1}{4I} \sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 \{(r_{T^b_{ijk}} - r_{C^b_{ijk}} - \lambda_0(d_{T^b_{ijk}} - d_{C^b_{ijk}})) \\ &\quad - (r_{T^a_{ijk}} - r_{C^a_{ijk}} - \lambda_0(d_{T^a_{ijk}} - d_{C^a_{ijk}}))\} \\ &= \frac{1}{4I} \sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 (\lambda - \lambda_0) \{(d_{T^b_{ijk}} - d_{C^b_{ijk}}) - (d_{T^a_{ijk}} - d_{C^a_{ijk}})\} \end{aligned}$$

where the last equality follows from the definition of  $\lambda$ . Hence, under the null hypothesis  $H_0^{\text{SW}} : \lambda = \lambda_0$ , we have

$$E[T_{\text{SW}}(\lambda_0) \mid \mathcal{F}] = 0. \tag{14}$$

Next, by the same bounding arguments used in Theorem 1 and Condition 1, there exists a

constant  $C$  such that

$$\frac{1}{I^2} \sum_{i=1}^I \mathbb{E}[V_{i,\text{SW}}^2(\lambda_0) \mid \mathcal{F}] \leq \frac{C}{4I^2} \sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 \left( y_{T_{ijk}}^2 + y_{C_{ijk}}^2 + y_{T_{ijk}}^2 + y_{C_{ijk}}^2 \right) \rightarrow 0$$

and

$$\frac{1}{I^2} \sum_{i=1}^I \mathbb{E}[V_{i,\text{SW}}^4(\lambda_0) \mid \mathcal{F}] \leq \frac{C}{4I^2} \sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 \left( y_{T_{ijk}}^4 + y_{C_{ijk}}^4 + y_{T_{ijk}}^4 + y_{C_{ijk}}^4 \right) \rightarrow 0$$

as  $I \rightarrow \infty$ . Therefore Lemma 3 implies

$$IS_{\text{SW}}^2(\lambda_0) - IE[S_{\text{SW}}^2(\lambda_0)] \xrightarrow{p} 0.$$

Applying Lemma 2 together with Condition 2 and (14) under  $H_0^{\text{SW}}$  yields

$$\frac{\sqrt{I}T_{\text{SW}}(\lambda_0)}{\sqrt{\text{Var}(\sqrt{I}T_{\text{SW}}(\lambda_0))}} \xrightarrow{d} \mathcal{N}(0, 1), \quad \text{as } I \rightarrow \infty.$$

Finally, define  $c_I = IE[S_{\text{SW}}^2(\lambda_0)] - \text{Var}(\sqrt{I}T_{\text{SW}}(\lambda_0))$ , which is nonnegative by Lemma 1. Then

$$IS_{\text{SW}}^2(\lambda_0) - \text{Var}(\sqrt{I}T_{\text{SW}}(\lambda_0)) - c_I = IS_{\text{SW}}^2(\lambda_0) - IE[S_{\text{SW}}^2(\lambda_0)] \xrightarrow{p} 0,$$

where  $c_I = 0$  holds if and only if

$$\begin{aligned} \mathbb{E}[V_{i,\text{SW}}(\lambda_0) \mid \mathcal{F}] &= \frac{1}{4} \sum_{j=1}^2 \sum_{k=1}^2 \{y_{T_{ijk}} - y_{C_{ijk}}\} - \{y_{T_{ijk}} - y_{C_{ijk}}\} \\ &= \frac{1}{4} \sum_{j=1}^2 \sum_{k=1}^2 \{(r_{T_{ijk}} - r_{C_{ijk}} - \lambda_0(d_{T_{ijk}} - d_{C_{ijk}})) - (r_{T_{ijk}} - r_{C_{ijk}} - \lambda_0(d_{T_{ijk}} - d_{C_{ijk}}))\} \\ &= \frac{1}{4} \sum_{j=1}^2 \sum_{k=1}^2 \{r_{T_{ijk}} - r_{C_{ijk}} - \lambda_0(d_{T_{ijk}} - d_{C_{ijk}})\} \mathbb{I}(S_{ijk} = \text{SW}) \\ &= \frac{1}{4} \sum_{j=1}^2 \sum_{k=1}^2 \{r_{d=1,ijk} - r_{d=0,ijk} - \lambda_0\} \mathbb{I}(S_{ijk} = \text{SW}) \end{aligned}$$

is constant across all  $i = 1, \dots, I$ .

Therefore,  $IS_{\text{SW}}^2(\lambda_0)$  is a large-sample conservative estimator for  $\text{Var}(\sqrt{I}T_{\text{SW}}(\lambda_0))$ , and can be used to construct asymptotically valid confidence intervals.  $\square$

To streamline exposition, we first present the proof of Theorem 4, as it contains the key technical ingredients used in biased randomization inference. Theorem 3 is proved by the same argument applied to a simpler test statistic; hence we prove Theorem 4 below and omit the nearly identical details for Theorem 3.

#### A.4 Proof of Theorem 4

*Proof.* The proof proceeds in three main steps: (1) establish stochastic dominance conditional on each treatment assignment realization, (2) construct moment bounds to replace the unknown expectation and variance under the null, and (3) verify asymptotic normality via a Lyapunov's condition.

**Step 1: Stochastic dominance construction.** There are four possible realizations of  $(T_{i1}, T_{i2})$ , each occurring with probability  $1/4$  under randomized treatment assignment within each pair. We consider each realization separately. Let  $\hat{\tau}_{i,SW}^{(t_1, t_2)}$  denote the value of  $\hat{\tau}_{i,SW}(\lambda_0)$  given the realization  $(T_{i1}, T_{i2}) = (t_1, t_2)$ , where

$$(t_1, t_2) \in \{(+1, +1), (+1, -1), (-1, +1), (-1, -1)\}.$$

For each realization, we decompose:

$$\hat{\tau}_{i,SW}^{(t_1, t_2)} = \bar{\tau}_{i,SW}^{(t_1, t_2)} + (2A_i - 1)\eta_{i,SW}^{(t_1, t_2)}$$

where  $\eta_{i,SW}^{(t_1, t_2)}$  are defined in Section A.1, and the quantities  $\hat{\tau}_{i,SW}^{(t_1, t_2)}$  and  $\bar{\tau}_{i,SW}^{(t_1, t_2)}$  are specified for each case as follows:

—

*Case 1:*  $(t_1, t_2) = (1, -1)$

$$\begin{aligned} \hat{\tau}_{i,SW}^{(1, -1)} &= A_i \{ (y_{T^b i 22} - y_{C^b i 21}) - (y_{T^a i 11} - y_{C^a i 12}) \} \\ &\quad + (1 - A_i) \{ (y_{T^b i 11} - y_{C^b i 12}) - (y_{T^a i 22} - y_{C^a i 21}) \}, \\ \bar{\tau}_{i,SW}^{(1, -1)} &= \frac{1}{2} \left[ (y_{T^b i 11} - y_{C^b i 12}) - (y_{T^a i 11} - y_{C^a i 12}) + (y_{T^b i 22} - y_{C^b i 21}) - (y_{T^a i 22} - y_{C^a i 21}) \right]. \end{aligned}$$

—

*Case 2:*  $(t_1, t_2) = (-1, -1)$

$$\begin{aligned} \hat{\tau}_{i,SW}^{(-1, -1)} &= A_i \{ (y_{T^b i 22} - y_{C^b i 21}) - (y_{T^a i 12} - y_{C^a i 11}) \} \\ &\quad + (1 - A_i) \{ (y_{T^b i 12} - y_{C^b i 11}) - (y_{T^a i 22} - y_{C^a i 21}) \}, \\ \bar{\tau}_{i,SW}^{(-1, -1)} &= \frac{1}{2} \left[ (y_{T^b i 12} - y_{C^b i 11}) - (y_{T^a i 12} - y_{C^a i 11}) + (y_{T^b i 22} - y_{C^b i 21}) - (y_{T^a i 22} - y_{C^a i 21}) \right]. \end{aligned}$$

Case 3:  $(t_1, t_2) = (-1, 1)$

$$\begin{aligned}\hat{\tau}_{i,\text{SW}}^{(-1,1)} &= A_i \{ (y_{T^b i 21} - y_{C^b i 22}) - (y_{T^a i 12} - y_{C^a i 11}) \} \\ &\quad + (1 - A_i) \{ (y_{T^b i 12} - y_{C^b i 11}) - (y_{T^a i 21} - y_{C^a i 22}) \}, \\ \bar{\tau}_{i,\text{SW}}^{(-1,1)} &= \frac{1}{2} \left[ (y_{T^b i 12} - y_{C^b i 11}) - (y_{T^a i 12} - y_{C^a i 11}) + (y_{T^b i 21} - y_{C^b i 22}) - (y_{T^a i 21} - y_{C^a i 22}) \right].\end{aligned}$$

Case 4:  $(t_1, t_2) = (1, 1)$

$$\begin{aligned}\hat{\tau}_{i,\text{SW}}^{(1,1)} &= A_i \{ (y_{T^b i 21} - y_{C^b i 22}) - (y_{T^a i 11} - y_{C^a i 12}) \} \\ &\quad + (1 - A_i) \{ (y_{T^b i 11} - y_{C^b i 12}) - (y_{T^a i 21} - y_{C^a i 22}) \}, \\ \bar{\tau}_{i,\text{SW}}^{(1,1)} &= \frac{1}{2} \left[ (y_{T^b i 11} - y_{C^b i 12}) - (y_{T^a i 11} - y_{C^a i 12}) + (y_{T^b i 21} - y_{C^b i 22}) - (y_{T^a i 21} - y_{C^a i 22}) \right].\end{aligned}$$

Under the partly biased randomization scheme, assignment probabilities satisfy:

$$\frac{1}{1 + \Gamma} \leq \pi_i = \Pr(A_i = 1) \leq \frac{\Gamma}{1 + \Gamma}, \quad \frac{1}{1 + \Gamma} \leq 1 - \pi_i = \Pr(A_i = 0) \leq \frac{\Gamma}{1 + \Gamma} \quad (15)$$

This implies:

$$\frac{1}{1 + \Gamma} \leq \Pr\{(2A_i - 1)\eta_{i,\text{SW}}^{(t_1, t_2)} = |\eta_{i,\text{SW}}^{(t_1, t_2)}|\} \leq \frac{\Gamma}{1 + \Gamma}$$

for  $\eta_{i,\text{SW}}^{(t_1, t_2)} \neq 0$ . If  $\eta_{i,\text{SW}}^{(t_1, t_2)} = 0$  then  $(2A_i - 1)\eta_{i,\text{SW}}^{(t_1, t_2)} = |\eta_{i,\text{SW}}^{(t_1, t_2)}| = 0$ , and all inequalities below hold trivially.

Define a binary random variable  $V_{i,\Gamma}$  taking values  $+1$  or  $-1$  with:

$$\Pr(V_{i,\Gamma} = +1) = \frac{\Gamma}{1 + \Gamma}, \quad \Pr(V_{i,\Gamma} = -1) = \frac{1}{1 + \Gamma}. \quad (16)$$

For the fixed  $\eta_{i,\text{SW}}^{(t_1, t_2)}$ , the variable  $V_{i,\Gamma}|\eta_{i,\text{SW}}^{(t_1, t_2)}|$  takes values  $\pm|\eta_{i,\text{SW}}^{(t_1, t_2)}|$  with mass on  $+|\eta_{i,\text{SW}}^{(t_1, t_2)}|$  equal to  $\Gamma/(1 + \Gamma)$ , which is at least the mass that  $(2A_i - 1)\eta_{i,\text{SW}}^{(t_1, t_2)}$  places on  $+|\eta_{i,\text{SW}}^{(t_1, t_2)}|$ . Therefore, for each fixed  $(t_1, t_2)$ ,  $V_{i,\Gamma}|\eta_{i,\text{SW}}^{(t_1, t_2)}|$  stochastically dominates  $(2A_i - 1)\eta_{i,\text{SW}}^{(t_1, t_2)}$ .

Consider the function  $f(x) = x - \frac{\Gamma-1}{\Gamma+1}|x|$ . For  $x \geq 0$ ,  $f(x) = \frac{2}{\Gamma+1}x$  and for  $x < 0$ ,  $f(x) = \frac{2\Gamma}{\Gamma+1}x$ . Since  $\Gamma > 0$  and  $f$  is continuous at  $x = 0$  with  $f(0) = 0$ ,  $f$  is strictly increasing on  $\mathbb{R}$ .

Define

$$U_{i,\Gamma}^{(t_1, t_2)} \equiv \bar{\tau}_{i,\text{SW}}^{(t_1, t_2)} + V_{i,\Gamma}|\eta_{i,\text{SW}}^{(t_1, t_2)}| - \left( \frac{\Gamma - 1}{\Gamma + 1} \right) |\bar{\tau}_{i,\text{SW}}^{(t_1, t_2)} + V_{i,\Gamma}|\eta_{i,\text{SW}}^{(t_1, t_2)}||$$

and

$$D_{i,\Gamma}^{(t_1,t_2)} \equiv \hat{\tau}_{i,\text{SW}}^{(t_1,t_2)} - \left( \frac{\Gamma-1}{\Gamma+1} \right) |\hat{\tau}_{i,\text{SW}}^{(t_1,t_2)}|$$

Since stochastic dominance is preserved under the monotone increasing  $f$ , we have:

$$\Pr(U_{i,\Gamma}^{(t_1,t_2)} \geq c) \geq \Pr(D_{i,\Gamma}^{(t_1,t_2)} \geq c) = \Pr(D_{i,\Gamma}^{\text{SW}}(\lambda_0) \geq c \mid (T_{i1}, T_{i2}) = (t_1, t_2)),$$

for any scalar  $c$  and each realization  $(T_{i1}, T_{i2}) = (t_1, t_2)$ , where the last equality uses the definition  $D_{i,\Gamma}^{(t_1,t_2)} = D_{i,\Gamma}$  on the event  $(T_{i1}, T_{i2}) = (t_1, t_2)$ .

By the law of total probability:

$$\begin{aligned} \Pr(D_{i,\Gamma}^{\text{SW}}(\lambda_0) \geq c) &= \sum_{(t_1,t_2)} \Pr(D_{i,\Gamma}^{\text{SW}}(\lambda_0) \geq c \mid (T_{i1}, T_{i2}) = (t_1, t_2)) \Pr((T_{i1}, T_{i2}) = (t_1, t_2)) \\ &= \frac{1}{4} \sum_{(t_1,t_2)} \Pr(D_{i,\Gamma}^{\text{SW}}(\lambda_0) \geq c \mid (T_{i1}, T_{i2}) = (t_1, t_2)) \\ &\leq \frac{1}{4} \sum_{(t_1,t_2)} \Pr(U_{i,\Gamma}^{(t_1,t_2)} \geq c), \end{aligned} \tag{17}$$

Define  $U_{i,\Gamma}$  as a random variable with:

$$\Pr(U_{i,\Gamma} = U_{i,\Gamma}^{(t_1,t_2)}) = \frac{1}{4} \quad \text{for } (t_1, t_2) \in \{(+1, +1), (+1, -1), (-1, +1), (-1, -1)\}$$

Using the law of total probability for  $U_{i,\Gamma}$ :

$$\begin{aligned} \Pr(U_{i,\Gamma} \geq c) &= \sum_{(t_1,t_2)} \Pr(U_{i,\Gamma} \geq c \mid U_{i,\Gamma} = U_{i,\Gamma}^{(t_1,t_2)}) \Pr(U_{i,\Gamma} = U_{i,\Gamma}^{(t_1,t_2)}) \\ &= \frac{1}{4} \sum_{(t_1,t_2)} \Pr(U_{i,\Gamma}^{(t_1,t_2)} \geq c) \end{aligned} \tag{18}$$

Combining the results from (17) and (18), we prove that  $U_{i,\Gamma}$  stochastically dominates  $D_{i,\Gamma}^{\text{SW}}(\lambda_0)$  for each  $i$ , i.e., for any scalar  $c$ :

$$\Pr(U_{i,\Gamma} \geq c) \geq \Pr(D_{i,\Gamma}^{\text{SW}}(\lambda_0) \geq c)$$

**Step 2: Moment bounds.** By Lemma 1,  $S_\Gamma^2$  provides an estimator of  $\text{var}(\overline{D}_\Gamma)$  which is conservative in expectation such that  $\mathbb{E}(S_\Gamma^2) \geq \text{var}(\overline{D}_\Gamma)$  for any  $\Gamma \geq 1$ . We then bound the expectation of  $\overline{D}_\Gamma$  by bounding the expectation of its stochastic upper bound  $\overline{U}_\Gamma$ .

For each  $i$ ,

$$\begin{aligned} E(U_{i,\Gamma}^{(t_1,t_2)}) &= \bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + \frac{\Gamma-1}{1+\Gamma} |\eta_{i,\text{SW}}^{(t_1,t_2)}| \\ &\quad - \left( \frac{\Gamma-1}{\Gamma+1} \right) \left\{ \frac{\Gamma}{\Gamma+1} |\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + |\eta_{i,\text{SW}}^{(t_1,t_2)}|| + \frac{1}{1+\Gamma} |\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} - |\eta_{i,\text{SW}}^{(t_1,t_2)}|| \right\} \end{aligned}$$

Following Lemma 2 in Fogarty (2020), with  $\Gamma \geq 1$ , the inequality

$$\frac{\Gamma}{\Gamma+1} |\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + |\eta_{i,\text{SW}}^{(t_1,t_2)}|| + \frac{1}{1+\Gamma} |\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} - |\eta_{i,\text{SW}}^{(t_1,t_2)}|| \geq |\eta_{i,\text{SW}}^{(t_1,t_2)}| + \frac{\Gamma-1}{\Gamma+1} \bar{\tau}_{i,\text{SW}}^{(t_1,t_2)}$$

always holds. Hence,

$$\begin{aligned} E(U_{i,\Gamma}^{(t_1,t_2)}) &\leq \bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + \frac{\Gamma-1}{1+\Gamma} |\eta_{i,\text{SW}}^{(t_1,t_2)}| - \left( \frac{\Gamma-1}{\Gamma+1} \right) \{ |\eta_{i,\text{SW}}^{(t_1,t_2)}| + \frac{\Gamma-1}{\Gamma+1} \bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} \} \\ &= \left[ 1 - \left( \frac{\Gamma-1}{\Gamma+1} \right)^2 \right] \bar{\tau}_{i,\text{SW}}^{(t_1,t_2)}. \end{aligned}$$

Averaging over the four treatment assignment cases of  $(T_{i1}, T_{i2})$ ,

$$\begin{aligned} E[U_{i,\Gamma}] &= \frac{1}{4} \sum_{t_1 \in \{1, -1\}} \sum_{t_2 \in \{1, -1\}} E[U_{i,\Gamma}^{(t_1,t_2)}] \\ &\leq \frac{1}{4} \left[ 1 - \left( \frac{\Gamma-1}{\Gamma+1} \right)^2 \right] \sum_{t_1 \in \{1, -1\}} \sum_{t_2 \in \{1, -1\}} \bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} \end{aligned}$$

Summing over all strata:

$$\begin{aligned} E \left[ \sum_{i=1}^I U_{i,\Gamma} \right] &\leq \frac{1}{4} \left[ 1 - \left( \frac{\Gamma-1}{\Gamma+1} \right)^2 \right] \sum_{i=1}^I \sum_{t_1 \in \{1, -1\}} \sum_{t_2 \in \{1, -1\}} \bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} \\ &= \frac{1}{4} \left[ 1 - \left( \frac{\Gamma-1}{\Gamma+1} \right)^2 \right] \sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 (\tau_{ijk}^b - \tau_{ijk}^a), \end{aligned}$$

where the second equality follows from the definition of  $\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)}$  with  $\tau_{ijk}^g = y_{T^g ijk} - y_{C^g ijk}$ . Under  $H_0^{SW} : \lambda = \lambda_0$ , we have

$$\sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 (\tau_{ijk}^b - \tau_{ijk}^a) = 0,$$

which implies  $E \left[ \sum_{i=1}^I U_{i,\Gamma} \right] \leq 0$ . Since  $D_{i,\Gamma}^{SW}(\lambda_0)$  is stochastically dominated by  $U_{i,\Gamma}$  for each  $i$ , it follows that  $E[\bar{D}_{\Gamma,\text{SW}}(\lambda_0)] \leq 0$  under  $H_0^{SW}$ .

**Step 3: Establish the asymptotic normality.** Given the independence across strata, to prove asymptotic normality of  $\sqrt{I\bar{D}}_{\Gamma,SW}(\lambda_0)$ , it suffices to show that Lyapunov's condition holds for  $\delta = 2$ .

For the conditional variance, we compute

$$\begin{aligned} & \text{Var}(D_{i,\Gamma}^{SW}(\lambda_0) \mid T_{i1} = t_1, T_{i2} = t_2) \\ &= \text{Var}(\hat{\tau}_{i,SW}^{(t_1,t_2)} - \left(\frac{\Gamma-1}{\Gamma+1}\right) |\hat{\tau}_{i,SW}^{(t_1,t_2)}| \mid T_{i1} = t_1, T_{i2} = t_2) \\ &= \text{Var}(\bar{\tau}_{i,SW}^{(t_1,t_2)} + (2A_i - 1)\eta_{i,SW}^{(t_1,t_2)} - \left(\frac{\Gamma-1}{\Gamma+1}\right) |\bar{\tau}_{i,SW}^{(t_1,t_2)} + (2A_i - 1)\eta_{i,SW}^{(t_1,t_2)}| \mid T_{i1} = t_1, T_{i2} = t_2) \end{aligned}$$

Since  $(2A_i - 1)$  takes values  $\pm 1$  with probability  $\pi_i$  and  $1 - \pi_i$ , respectively, we have

$$\begin{aligned} & \mathbb{E} \left[ \bar{\tau}_{i,SW}^{(t_1,t_2)} + (2A_i - 1)\eta_{i,SW}^{(t_1,t_2)} - \frac{\Gamma-1}{\Gamma+1} |\bar{\tau}_{i,SW}^{(t_1,t_2)} + (2A_i - 1)\eta_{i,SW}^{(t_1,t_2)}| \right] \\ &= \pi_i \left( \bar{\tau}_{i,SW}^{(t_1,t_2)} + \eta_{i,SW}^{(t_1,t_2)} - \frac{\Gamma-1}{\Gamma+1} |\bar{\tau}_{i,SW}^{(t_1,t_2)} + \eta_{i,SW}^{(t_1,t_2)}| \right) + (1 - \pi_i) \left( \bar{\tau}_{i,SW}^{(t_1,t_2)} - \eta_{i,SW}^{(t_1,t_2)} - \frac{\Gamma-1}{\Gamma+1} |\bar{\tau}_{i,SW}^{(t_1,t_2)} - \eta_{i,SW}^{(t_1,t_2)}| \right) \end{aligned}$$

and

$$\begin{aligned} & \mathbb{E} \left[ \left( \bar{\tau}_{i,SW}^{(t_1,t_2)} + (2A_i - 1)\eta_{i,SW}^{(t_1,t_2)} - \frac{\Gamma-1}{\Gamma+1} |\bar{\tau}_{i,SW}^{(t_1,t_2)} + (2A_i - 1)\eta_{i,SW}^{(t_1,t_2)}| \right)^2 \right] \\ &= \pi_i \left( \bar{\tau}_{i,SW}^{(t_1,t_2)} + \eta_{i,SW}^{(t_1,t_2)} - \frac{\Gamma-1}{\Gamma+1} |\bar{\tau}_{i,SW}^{(t_1,t_2)} + \eta_{i,SW}^{(t_1,t_2)}| \right)^2 + (1 - \pi_i) \left( \bar{\tau}_{i,SW}^{(t_1,t_2)} - \eta_{i,SW}^{(t_1,t_2)} - \frac{\Gamma-1}{\Gamma+1} |\bar{\tau}_{i,SW}^{(t_1,t_2)} - \eta_{i,SW}^{(t_1,t_2)}| \right)^2 \end{aligned}$$



Then by the definition of variance, we obtain

$$\begin{aligned}
& \text{Var}(D_{i,\Gamma}^{\text{SW}}(\lambda_0) \mid T_{i1} = t_1, T_{i2} = t_2) \\
&= \text{Var}(\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + (2A_i - 1)\eta_{i,\text{SW}}^{(t_1,t_2)} - \left(\frac{\Gamma - 1}{\Gamma + 1}\right) |\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + (2A_i - 1)\eta_{i,\text{SW}}^{(t_1,t_2)}|) \\
&= \text{E} \left[ \left( \bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + (2A_i - 1)\eta_{i,\text{SW}}^{(t_1,t_2)} - \frac{\Gamma - 1}{\Gamma + 1} |\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + (2A_i - 1)\eta_{i,\text{SW}}^{(t_1,t_2)}| \right)^2 \right] \\
&\quad - \left( \text{E} \left[ \bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + (2A_i - 1)\eta_{i,\text{SW}}^{(t_1,t_2)} - \frac{\Gamma - 1}{\Gamma + 1} |\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + (2A_i - 1)\eta_{i,\text{SW}}^{(t_1,t_2)}| \right] \right)^2 \\
&= \pi_i(1 - \pi_i) \left( \bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + \eta_{i,\text{SW}}^{(t_1,t_2)} - \frac{\Gamma - 1}{\Gamma + 1} |\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + \eta_{i,\text{SW}}^{(t_1,t_2)}| \right)^2 \\
&\quad + \pi_i(1 - \pi_i) \left( \bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} - \eta_{i,\text{SW}}^{(t_1,t_2)} - \frac{\Gamma - 1}{\Gamma + 1} |\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} - \eta_{i,\text{SW}}^{(t_1,t_2)}| \right)^2 \\
&\quad - 2\pi_i(1 - \pi_i) \left( \bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + \eta_{i,\text{SW}}^{(t_1,t_2)} - \frac{\Gamma - 1}{\Gamma + 1} |\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + \eta_{i,\text{SW}}^{(t_1,t_2)}| \right) \left( \bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} - \eta_{i,\text{SW}}^{(t_1,t_2)} - \frac{\Gamma - 1}{\Gamma + 1} |\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} - \eta_{i,\text{SW}}^{(t_1,t_2)}| \right) \\
&= \pi_i(1 - \pi_i) \left\{ 2\eta_{i,\text{SW}}^{(t_1,t_2)} - \frac{\Gamma - 1}{\Gamma + 1} (|\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + \eta_{i,\text{SW}}^{(t_1,t_2)}| - |\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} - \eta_{i,\text{SW}}^{(t_1,t_2)}|) \right\}^2
\end{aligned}$$

Under the sensitivity model  $\pi_i \in [1/(1 + \Gamma), \Gamma/(1 + \Gamma)]$  with  $\Gamma \geq 1$ , the product  $\pi_i(1 - \pi_i)$  is minimized at the endpoints, yielding

$$\pi_i(1 - \pi_i) \geq \frac{\Gamma}{\Gamma + 1} \cdot \frac{1}{\Gamma + 1}.$$

Next, we bound the absolute-value term using the triangle inequality: for any real numbers  $x$  and  $y$ ,

$$|x + y| - |x - y| \leq |(x + y) - (x - y)| = 2|y|.$$

Applying this with  $x = \bar{\tau}_{i,\text{SW}}^{(t_1,t_2)}$  and  $y = \eta_{i,\text{SW}}^{(t_1,t_2)}$  gives

$$2\eta_{i,\text{SW}}^{(t_1,t_2)} - \frac{\Gamma - 1}{\Gamma + 1} (|\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + \eta_{i,\text{SW}}^{(t_1,t_2)}| - |\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} - \eta_{i,\text{SW}}^{(t_1,t_2)}|) \geq \begin{cases} 2\eta_{i,\text{SW}}^{(t_1,t_2)} \cdot \frac{2}{\Gamma + 1}, & \eta_{i,\text{SW}}^{(t_1,t_2)} > 0, \\ 2\eta_{i,\text{SW}}^{(t_1,t_2)} \cdot \frac{2\Gamma}{\Gamma + 1}, & \eta_{i,\text{SW}}^{(t_1,t_2)} < 0. \end{cases}$$

Since  $\Gamma \geq 1$ , in either case we have the conservative bound

$$\left\{ 2\eta_{i,\text{SW}}^{(t_1,t_2)} - \frac{\Gamma - 1}{\Gamma + 1} (|\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} + \eta_{i,\text{SW}}^{(t_1,t_2)}| - |\bar{\tau}_{i,\text{SW}}^{(t_1,t_2)} - \eta_{i,\text{SW}}^{(t_1,t_2)}|) \right\}^2 \geq \frac{16 \left( \eta_{i,\text{SW}}^{(t_1,t_2)} \right)^2}{(1 + \Gamma)^2}.$$

Combining with the bound on  $\pi_i(1 - \pi_i)$ , we obtain

$$\text{Var}(D_{i,\Gamma}^{\text{SW}}(\lambda_0) \mid T_{i1} = t_1, T_{i2} = t_2) \geq 16 \frac{\Gamma}{\Gamma + 1} \left( \frac{1}{\Gamma + 1} \right)^3 \left( \eta_{i,\text{SW}}^{(t_1, t_2)} \right)^2.$$

By the law of total variance, we have

$$\begin{aligned} \text{Var}(D_{i,\Gamma}^{\text{SW}}(\lambda_0)) &= \text{E} \left[ \text{Var}(D_{i,\Gamma}^{\text{SW}}(\lambda_0) \mid T_{i1}, T_{i2}) \right] + \text{Var} \left( \text{E}[D_{i,\Gamma}^{\text{SW}}(\lambda_0) \mid T_{i1}, T_{i2}] \right) \\ &\geq \text{E} \left[ \text{Var}(D_{i,\Gamma}^{\text{SW}}(\lambda_0) \mid T_{i1}, T_{i2}) \right] \\ &\geq \text{E} \left[ 16 \frac{\Gamma}{\Gamma + 1} \left( \frac{1}{\Gamma + 1} \right)^3 \left( \eta_{i,\text{SW}}^{(T_{i1}, T_{i2})} \right)^2 \right] \\ &= 16 \frac{\Gamma}{\Gamma + 1} \left( \frac{1}{\Gamma + 1} \right)^3 \sum_{t_1 \in \{1, -1\}} \sum_{t_2 \in \{1, -1\}} \text{Pr} \{ (T_{i1}, T_{i2}) = (t_1, t_2) \} \left( \eta_{i,\text{SW}}^{(t_1, t_2)} \right)^2 \\ &= \frac{4\Gamma}{(\Gamma + 1)^4} \sum_{t_1 \in \{1, -1\}} \sum_{t_2 \in \{1, -1\}} \left( \eta_{i,\text{SW}}^{(t_1, t_2)} \right)^2. \end{aligned}$$

Under the partly biased randomization scheme,

$$\begin{aligned} \text{E}(D_{i,\Gamma}^{\text{SW}}(\lambda_0)) &= \frac{\pi_i}{4} \sum_{k_1 \neq k'_1} \sum_{k_2 \neq k'_2} \left[ \left( y_{C^a i 1 k_1} - y_{T^a i 1 k'_1} + y_{T^b i 2 k_2} - y_{C^b i 2 k'_2} \right) \right. \\ &\quad \left. - \frac{\Gamma - 1}{\Gamma + 1} \left| y_{C^a i 1 k_1} - y_{T^a i 1 k'_1} + y_{T^b i 2 k_2} - y_{C^b i 2 k'_2} \right| \right] \\ &\quad + \frac{1 - \pi_i}{4} \sum_{k_1 \neq k'_1} \sum_{k_2 \neq k'_2} \left[ \left( y_{C^a i 2 k_1} - y_{T^a i 2 k'_1} + y_{T^b i 1 k_2} - y_{C^b i 1 k'_2} \right) \right. \\ &\quad \left. - \frac{\Gamma - 1}{\Gamma + 1} \left| y_{C^a i 2 k_1} - y_{T^a i 2 k'_1} + y_{T^b i 1 k_2} - y_{C^b i 1 k'_2} \right| \right]. \end{aligned}$$

By Hölder's inequality, for each stratum  $i$  there exists  $C_i < \infty$  such that

$$\sum_{i=1}^I \text{E}([D_{i,\Gamma}^{\text{SW}}(\lambda_0)]^2) \leq \sum_{i=1}^I C_i \sum_{j=1}^2 \sum_{k=1}^2 \left\{ y_{T^a i j k}^2 + y_{C^a i j k}^2 + y_{T^b i j k}^2 + y_{C^b i j k}^2 \right\},$$

Similarly,

$$\begin{aligned}
\mathbb{E}([D_{i,\Gamma}^{\text{SW}}(\lambda_0)]^4) &= \sum_{t_1 \in \{1, -1\}} \sum_{t_2 \in \{1, -1\}} \mathbb{E}([D_{i,\Gamma}^{\text{SW}}(\lambda_0)]^4 \mid (T_{i1}, T_{i2}) = (t_1, t_2)) \cdot \Pr\{(T_{i1}, T_{i2}) = (t_1, t_2)\} \\
&= \frac{1}{4} \sum_{t_1 \in \{1, -1\}} \sum_{t_2 \in \{1, -1\}} \mathbb{E}([D_{i,\Gamma}^{\text{SW}}(\lambda_0)]^4 \mid (T_{i1}, T_{i2}) = (t_1, t_2)) \\
&\leq \frac{1}{4} \sum_{t_1 \in \{1, -1\}} \sum_{t_2 \in \{1, -1\}} 128 \left( \frac{\Gamma}{1 + \Gamma} \right)^4 \left( (\bar{\tau}_{i,\text{SW}}^{(t_1, t_2)})^4 + (\eta_{i,\text{SW}}^{(t_1, t_2)})^4 \right) \\
&\leq C' \sum_{j=1}^2 \sum_{k=1}^2 \left\{ y_{T^a ijk}^4 + y_{C^a ijk}^4 + y_{T^b ijk}^4 + y_{C^b ijk}^4 \right\}
\end{aligned} \tag{19}$$

for some constant  $C' < \infty$ , where (19) follows from Lemma 5 of Fogarty (2020).

Therefore, under Conditions 1 and 3, we have

$$\mathbb{E}(\bar{D}_{\Gamma, \text{SW}}(\lambda_0)) = O(1), \quad \lim_{I \rightarrow \infty} I^{-2} \sum_{i=1}^I \mathbb{E}([D_{i,\Gamma}^{\text{SW}}(\lambda_0)]^2) = 0, \quad \lim_{I \rightarrow \infty} I^{-2} \sum_{i=1}^I \mathbb{E}([D_{i,\Gamma}^{\text{SW}}(\lambda_0)]^4) = 0,$$

and

$$\lim_{I \rightarrow \infty} I^{-1} \sum_{i=1}^I \text{var}(D_{i,\Gamma}^{\text{SW}}(\lambda_0)) \geq \frac{4\Gamma}{(\Gamma + 1)^4} C.$$

Then Lemma 3 implies

$$IS_{\Gamma, \text{SW}}^2(\lambda_0) - IE(S_{\Gamma, \text{SW}}^2(\lambda_0)) \xrightarrow{p} 0, \tag{20}$$

and Lemma 2 yields

$$\frac{\sqrt{I} \bar{D}_{\Gamma, \text{SW}}(\lambda_0) - \mathbb{E}(\sqrt{I} \bar{D}_{\Gamma, \text{SW}}(\lambda_0))}{\sqrt{\text{var}(\sqrt{I} \bar{D}_{\Gamma, \text{SW}}(\lambda_0))}} \xrightarrow{d} \mathcal{N}(0, 1), \quad \text{as } I \rightarrow \infty.$$

Along with the moment bounds from Step 2, if the treatment assignment satisfies (5) at  $\Gamma$  and  $H_0^{\text{SW}}$  holds, then

$$\lim_{I \rightarrow \infty} \Pr\{\sqrt{I} \bar{D}_{\Gamma, \text{SW}}(\lambda_0) \geq \Phi^{-1}(1 - \alpha) \sqrt{IE(S_{\Gamma, \text{SW}}^2(\lambda_0))}\} \leq \alpha.$$

This, in combination with (20), yields the conclusion of the theorem.  $\square$

### A.5 Proof of Theorem 3

*Proof.* Let  $\hat{\tau}_{i, \text{ACO}}^{(t_1, t_2)}$  denote the value of  $\hat{\tau}_{i, \text{ACO}}(\kappa_0)$  given the realization  $(T_{i1}, T_{i2}) = (t_1, t_2)$ , where  $(t_1, t_2) \in \{(+1, +1), (+1, -1), (-1, +1), (-1, -1)\}$ . For each realization, we decom-

pose:

$$\hat{\tau}_{i,\text{ACO}}^{(t_1,t_2)} = \bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)} + (2A_i - 1)\eta_{i,\text{ACO}}^{(t_1,t_2)}$$

where  $\eta_{i,\text{ACO}}^{(t_1,t_2)}$  are defined in Section A.1, and the quantities  $\hat{\tau}_{i,\text{ACO}}^{(t_1,t_2)}$  and  $\bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)}$  are specified for each case as follows:

—  
*Case 1:*  $(t_1, t_2) = (1, -1)$

$$\begin{aligned}\hat{\tau}_{i,\text{ACO}}^{(1,-1)} &= A_i(y_{T^a i 11} - y_{C^a i 12}) + (1 - A_i)(y_{T^a i 22} - y_{C^a i 21}), \\ \bar{\tau}_{i,\text{ACO}}^{(1,-1)} &= \frac{1}{2}[(y_{T^a i 11} - y_{C^a i 12}) + (y_{T^a i 22} - y_{C^a i 21})].\end{aligned}$$

—  
*Case 2:*  $(t_1, t_2) = (-1, -1)$

$$\begin{aligned}\hat{\tau}_{i,\text{ACO}}^{(-1,-1)} &= A_i(y_{T^a i 12} - y_{C^a i 11}) + (1 - A_i)(y_{T^a i 22} - y_{C^a i 21}), \\ \bar{\tau}_{i,\text{ACO}}^{(-1,-1)} &= \frac{1}{2}[(y_{T^a i 12} - y_{C^a i 11}) + (y_{T^a i 22} - y_{C^a i 21})].\end{aligned}$$

—  
*Case 3:*  $(t_1, t_2) = (-1, 1)$

$$\begin{aligned}\hat{\tau}_{i,\text{ACO}}^{(-1,1)} &= A_i\{(y_{T^a i 12} - y_{C^a i 11})\} + (1 - A_i)\{(y_{T^a i 21} - y_{C^a i 22})\}, \\ \bar{\tau}_{i,\text{ACO}}^{(-1,1)} &= \frac{1}{2}[(y_{T^a i 12} - y_{C^a i 11}) + (y_{T^a i 21} - y_{C^a i 22})].\end{aligned}$$

—  
*Case 4:*  $(t_1, t_2) = (1, 1)$

$$\begin{aligned}\hat{\tau}_{i,\text{ACO}}^{(1,1)} &= A_i(y_{T^a i 11} - y_{C^a i 12}) + (1 - A_i)(y_{T^a i 21} - y_{C^a i 22}), \\ \bar{\tau}_{i,\text{ACO}}^{(1,1)} &= \frac{1}{2}[(y_{T^a i 11} - y_{C^a i 12}) + (y_{T^a i 21} - y_{C^a i 22})].\end{aligned}$$

Define

$$U_{i,\Gamma,\text{ACO}}^{(t_1,t_2)} \equiv \bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)} + V_{i,\Gamma}|\eta_{i,\text{ACO}}^{(t_1,t_2)}| - \left(\frac{\Gamma - 1}{\Gamma + 1}\right)|\bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)} + V_{i,\Gamma}|\eta_{i,\text{ACO}}^{(t_1,t_2)}|$$

Let  $U_{i,\Gamma}^{\text{ACO}}$  be a random variable taking

$$\Pr(U_{i,\Gamma}^{\text{ACO}} = U_{i,\Gamma,\text{ACO}}^{(t_1,t_2)}) = \frac{1}{4}, \quad \text{for } (t_1, t_2) \in \{(+1, +1), (+1, -1), (-1, +1), (-1, -1)\}$$

Following the same logic as in the proof of Theorem 4,  $U_{i,\Gamma}^{\text{ACO}}$  stochastically dominates

$D_{i,\Gamma}^{\text{ACO}}(\kappa_0)$  for each  $i$ , i.e., for any scalar  $c$ :

$$\Pr(U_{i,\Gamma}^{\text{ACO}} \geq c) \geq \Pr(D_{i,\Gamma}^{\text{ACO}}(\kappa_0) \geq c)$$

To bound the expectation of  $\overline{D}_{\Gamma,\text{ACO}}(\kappa_0)$ , it therefore suffices to bound the expectation of its stochastic upper bound  $\overline{U}_{i,\Gamma}^{\text{ACO}}$ .

For each  $i$ ,

$$\begin{aligned} \mathbb{E}(U_{i,\Gamma,\text{ACO}}^{(t_1,t_2)}) &= \bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)} + \frac{\Gamma-1}{1+\Gamma} |\eta_{i,\text{ACO}}^{(t_1,t_2)}| \\ &\quad - \left( \frac{\Gamma-1}{\Gamma+1} \right) \left\{ \frac{\Gamma}{\Gamma+1} |\bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)} + |\eta_{i,\text{ACO}}^{(t_1,t_2)}|| + \frac{1}{1+\Gamma} |\bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)} - |\eta_{i,\text{ACO}}^{(t_1,t_2)}|| \right\} \end{aligned}$$

By Lemma 2 of Fogarty (2020), for  $\Gamma \geq 1$ , the inequality

$$\frac{\Gamma}{\Gamma+1} |\bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)} + |\eta_{i,\text{ACO}}^{(t_1,t_2)}|| + \frac{1}{1+\Gamma} |\bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)} - |\eta_{i,\text{ACO}}^{(t_1,t_2)}|| \geq |\eta_{i,\text{ACO}}^{(t_1,t_2)}| + \frac{\Gamma-1}{\Gamma+1} \bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)}$$

always holds. Hence,

$$\begin{aligned} \mathbb{E}(U_{i,\Gamma,\text{ACO}}^{(t_1,t_2)}) &\leq \bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)} + \frac{\Gamma-1}{1+\Gamma} |\eta_{i,\text{ACO}}^{(t_1,t_2)}| - \left( \frac{\Gamma-1}{\Gamma+1} \right) \{ |\eta_{i,\text{ACO}}^{(t_1,t_2)}| + \frac{\Gamma-1}{\Gamma+1} \bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)} \} \\ &= \left[ 1 - \left( \frac{\Gamma-1}{\Gamma+1} \right)^2 \right] \bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)}. \end{aligned}$$

Averaging over all four treatment assignment cases of  $(T_{i1}, T_{i2})$ ,

$$\begin{aligned} \mathbb{E}[U_{i,\Gamma}^{\text{ACO}}] &= \frac{1}{4} \sum_{t_1 \in \{1,-1\}} \sum_{t_2 \in \{1,-1\}} \mathbb{E}[U_{i,\Gamma,\text{ACO}}^{(t_1,t_2)}] \\ &\leq \frac{1}{4} \left[ 1 - \left( \frac{\Gamma-1}{\Gamma+1} \right)^2 \right] \sum_{t_1 \in \{1,-1\}} \sum_{t_2 \in \{1,-1\}} \bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)} \end{aligned}$$

Summing over all strata:

$$\begin{aligned} \mathbb{E} \left[ \sum_{i=1}^I U_{i,\Gamma}^{\text{ACO}} \right] &\leq \frac{1}{4} \left[ 1 - \left( \frac{\Gamma-1}{\Gamma+1} \right)^2 \right] \sum_{i=1}^I \sum_{t_1 \in \{1,-1\}} \sum_{t_2 \in \{1,-1\}} \bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)} \\ &= \frac{1}{4} \left[ 1 - \left( \frac{\Gamma-1}{\Gamma+1} \right)^2 \right] \sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 (y_{T^{a_{ijk}}} - y_{C^{a_{ijk}}}), \end{aligned}$$

where the last equality follows from the definition of  $\bar{\tau}_{i,\text{ACO}}^{(t_1,t_2)}$ .

Under the null hypothesis  $H_0^{\text{ACO}} : \kappa = \kappa_0$ , we have

$$\sum_{i=1}^I \sum_{j=1}^2 \sum_{k=1}^2 (y_{T^{a_{ijk}}} - y_{C^{a_{ijk}}}) = 0,$$

which implies  $\mathbb{E} \left[ \sum_{i=1}^I U_{i,\Gamma}^{\text{ACO}} \right] \leq 0$ . Since  $D_{i,\Gamma}^{\text{ACO}}(\kappa_0)$  is stochastically dominated by  $U_{i,\Gamma}^{\text{ACO}}$  for all  $i$ , it follows that

$$\mathbb{E}[\overline{D}_{\Gamma,\text{ACO}}(\kappa_0)] \leq 0 \quad \text{under } H_0^{\text{ACO}}.$$

The remaining steps follow directly from the argument used in the proof of Theorem 4.  $\square$

## Supplemental Material B: Additional simulation studies

### B.1 Additional simulation results for switchers

Table S2: Simulation results over 1000 replicates for varying strata sizes ( $I$ ), proportions of switchers ( $p$ ), and mean treatment effects among switchers ( $\mu$ ), under a uniform distribution of treatment effects among switchers:  $\tau_{ijk}^{SW} \sim \text{Unif}[\mu - \sqrt{3}, \mu + \sqrt{3}]$ .

I	p	$\mu$	level	power	$\bar{\tau}_a$	$\bar{\tau}_b$	$\bar{\lambda}$	CI		100× SD[T( $\lambda$ )]	100× $S(\lambda)$	100× SD[T(0)]	100× $S(0)$
								length	coverage (%)				
$\tau_{ijk}^{SW} \sim \text{Unif}[\mu - \sqrt{3}, \mu + \sqrt{3}]$													
100	0.30	0.00	0.06	0.06	0.14	0.44	0.00	4.88	94.37	6.11	6.15	6.11	6.15
100	0.30	0.25	0.06	0.07	0.14	0.44	0.25	4.88	94.49	6.09	6.14	6.10	6.15
100	0.30	0.50	0.06	0.09	0.14	0.44	0.50	4.81	94.08	6.15	6.18	6.14	6.18
100	0.30	1.00	0.06	0.23	0.14	0.44	1.00	5.01	94.37	6.40	6.42	6.26	6.31
100	0.50	0.00	0.05	0.05	0.10	0.60	-0.00	2.20	94.60	6.08	6.13	6.08	6.13
100	0.50	0.25	0.05	0.08	0.10	0.60	0.25	2.21	94.20	6.08	6.13	6.09	6.15
100	0.50	0.50	0.05	0.16	0.10	0.60	0.50	2.22	94.90	6.10	6.15	6.12	6.16
100	0.50	1.00	0.04	0.49	0.10	0.60	1.00	2.32	94.90	6.31	6.37	6.30	6.40
100	0.70	0.00	0.06	0.06	0.06	0.76	-0.00	1.44	93.90	6.04	6.12	6.05	6.13
100	0.70	0.25	0.06	0.12	0.06	0.76	0.25	1.43	93.90	6.02	6.10	6.03	6.12
100	0.70	0.50	0.05	0.31	0.06	0.76	0.50	1.44	94.60	6.06	6.13	6.09	6.16
100	0.70	1.00	0.05	0.79	0.06	0.76	1.00	1.49	93.80	6.22	6.32	6.31	6.44
500	0.30	0.00	0.04	0.04	0.14	0.44	0.00	1.55	96.20	2.73	2.75	2.73	2.75
500	0.30	0.25	0.07	0.11	0.14	0.44	0.25	1.53	93.40	2.73	2.75	2.73	2.75
500	0.30	0.50	0.05	0.28	0.14	0.44	0.50	1.56	94.30	2.75	2.76	2.75	2.76
500	0.30	1.00	0.05	0.74	0.14	0.44	1.00	1.63	95.30	2.86	2.88	2.80	2.84
500	0.50	0.00	0.04	0.04	0.10	0.60	-0.00	0.87	95.80	2.72	2.75	2.72	2.75
500	0.50	0.25	0.04	0.22	0.10	0.60	0.25	0.87	95.40	2.72	2.75	2.72	2.75
500	0.50	0.50	0.06	0.61	0.10	0.60	0.50	0.87	94.30	2.73	2.76	2.74	2.76
500	0.50	1.00	0.04	0.99	0.10	0.60	1.00	0.90	95.70	2.83	2.85	2.82	2.86
500	0.70	0.00	0.05	0.05	0.06	0.76	-0.00	0.61	94.50	2.70	2.74	2.70	2.74
500	0.70	0.25	0.04	0.34	0.06	0.76	0.25	0.61	95.00	2.70	2.74	2.71	2.75
500	0.70	0.50	0.04	0.87	0.06	0.76	0.50	0.61	95.30	2.71	2.75	2.73	2.77
500	0.70	1.00	0.04	1.00	0.06	0.76	1.00	0.63	94.90	2.78	2.82	2.82	2.87
1000	0.30	0.00	0.05	0.05	0.14	0.44	-0.00	1.04	94.40	1.93	1.94	1.93	1.94
1000	0.30	0.25	0.05	0.15	0.14	0.44	0.25	1.04	94.40	1.93	1.95	1.94	1.95
1000	0.30	0.50	0.04	0.49	0.14	0.44	0.50	1.05	96.30	1.95	1.96	1.94	1.96
1000	0.30	1.00	0.05	0.97	0.14	0.44	1.00	1.10	94.80	2.03	2.04	1.98	2.00
1000	0.50	0.00	0.05	0.06	0.10	0.60	-0.00	0.61	94.10	1.92	1.94	1.92	1.94
1000	0.50	0.25	0.06	0.36	0.10	0.60	0.25	0.61	94.10	1.92	1.94	1.92	1.94
1000	0.50	0.50	0.04	0.89	0.10	0.60	0.50	0.61	94.40	1.93	1.95	1.94	1.96
1000	0.50	1.00	0.03	1.00	0.10	0.60	1.00	0.63	95.90	2.00	2.02	2.00	2.03
1000	0.70	0.00	0.04	0.04	0.06	0.76	0.00	0.43	95.30	1.91	1.94	1.91	1.94
1000	0.70	0.25	0.04	0.60	0.06	0.76	0.25	0.43	95.20	1.91	1.94	1.92	1.94
1000	0.70	0.50	0.04	0.99	0.06	0.76	0.50	0.43	95.30	1.92	1.95	1.93	1.96
1000	0.70	1.00	0.05	1.00	0.06	0.76	1.00	0.44	94.40	1.97	1.99	2.00	2.03

Table S3: Simulation results over 1000 replicates for varying strata sizes ( $I$ ), proportions of switchers ( $p$ ), and mean treatment effects among switchers ( $\mu$ ), under an exponential distribution of treatment effects among switchers:  $\tau_{ijk}^{SW} \sim \text{Exp}(1/\mu)$ .

I	p	$\mu$	level	power	$\bar{\iota}_a$	$\bar{\iota}_b$	$\bar{\lambda}$	CI		100× SD[T( $\lambda$ )]	100× $S(\lambda)$	100× SD[T(0)]	100× $S(0)$
								length	coverage (%)				
$\tau_{ijk}^{SW} \sim \mathbf{Exp}(1/\mu)$													
100	0.30	0.00	0.06	0.06	0.14	0.44	0.00	4.68	94.68	5.83	5.84	5.83	5.84
100	0.30	0.25	0.05	0.08	0.14	0.44	0.25	4.78	94.58	5.85	5.84	5.86	5.85
100	0.30	0.50	0.05	0.10	0.14	0.44	0.50	4.73	94.88	5.95	5.93	5.94	5.93
100	0.30	1.00	0.06	0.22	0.14	0.44	1.00	4.95	94.87	6.43	6.44	6.29	6.34
100	0.50	0.00	0.05	0.05	0.10	0.60	0.00	2.03	94.60	5.61	5.60	5.61	5.60
100	0.50	0.25	0.07	0.10	0.10	0.60	0.25	2.04	92.70	5.64	5.64	5.65	5.65
100	0.50	0.50	0.06	0.20	0.10	0.60	0.50	2.11	93.60	5.76	5.76	5.77	5.78
100	0.50	1.00	0.05	0.52	0.10	0.60	1.00	2.30	95.10	6.30	6.35	6.28	6.37
100	0.70	0.00	0.07	0.07	0.06	0.76	0.00	1.27	93.50	5.38	5.37	5.38	5.37
100	0.70	0.25	0.06	0.12	0.06	0.76	0.25	1.28	93.80	5.41	5.40	5.43	5.42
100	0.70	0.50	0.06	0.35	0.06	0.76	0.50	1.31	94.10	5.57	5.58	5.61	5.62
100	0.70	1.00	0.05	0.78	0.06	0.76	1.00	1.48	95.10	6.22	6.29	6.31	6.40
500	0.30	0.00	0.05	0.05	0.14	0.44	0.00	1.48	95.40	2.62	2.62	2.62	2.62
500	0.30	0.25	0.05	0.12	0.14	0.44	0.25	1.47	94.90	2.61	2.61	2.62	2.62
500	0.30	0.50	0.03	0.28	0.14	0.44	0.50	1.48	96.50	2.66	2.66	2.65	2.66
500	0.30	1.00	0.05	0.76	0.14	0.44	1.00	1.62	93.80	2.86	2.88	2.81	2.83
500	0.50	0.00	0.06	0.06	0.10	0.60	0.00	0.79	93.90	2.51	2.51	2.51	2.51
500	0.50	0.25	0.04	0.23	0.10	0.60	0.25	0.80	95.80	2.52	2.52	2.53	2.53
500	0.50	0.50	0.05	0.69	0.10	0.60	0.50	0.82	95.10	2.58	2.58	2.59	2.59
500	0.50	1.00	0.04	0.99	0.10	0.60	1.00	0.91	95.90	2.83	2.85	2.82	2.86
500	0.70	0.00	0.04	0.04	0.06	0.76	0.00	0.54	95.90	2.41	2.40	2.41	2.40
500	0.70	0.25	0.04	0.45	0.06	0.76	0.25	0.54	94.90	2.42	2.42	2.43	2.43
500	0.70	0.50	0.05	0.94	0.06	0.76	0.50	0.56	94.90	2.49	2.50	2.51	2.52
500	0.70	1.00	0.05	1.00	0.06	0.76	1.00	0.63	94.40	2.78	2.82	2.82	2.87
1000	0.30	0.00	0.06	0.06	0.14	0.44	0.00	0.99	94.40	1.85	1.85	1.85	1.85
1000	0.30	0.25	0.06	0.19	0.14	0.44	0.25	0.99	94.20	1.85	1.85	1.85	1.85
1000	0.30	0.50	0.06	0.50	0.14	0.44	0.50	1.01	93.80	1.88	1.88	1.88	1.88
1000	0.30	1.00	0.05	0.97	0.14	0.44	1.00	1.09	94.90	2.03	2.04	1.98	2.00
1000	0.50	0.00	0.05	0.05	0.10	0.60	0.00	0.55	95.20	1.78	1.77	1.78	1.77
1000	0.50	0.25	0.06	0.43	0.10	0.60	0.25	0.55	93.90	1.78	1.78	1.79	1.79
1000	0.50	0.50	0.06	0.93	0.10	0.60	0.50	0.57	93.30	1.82	1.83	1.83	1.84
1000	0.50	1.00	0.05	1.00	0.10	0.60	1.00	0.63	94.70	2.00	2.02	1.99	2.03
1000	0.70	0.00	0.05	0.05	0.06	0.76	0.00	0.37	95.20	1.70	1.70	1.70	1.70
1000	0.70	0.25	0.05	0.71	0.06	0.76	0.25	0.38	94.60	1.71	1.72	1.72	1.72
1000	0.70	0.50	0.03	1.00	0.06	0.76	0.50	0.39	96.00	1.76	1.77	1.78	1.79
1000	0.70	1.00	0.06	1.00	0.06	0.76	1.00	0.44	93.20	1.96	1.99	1.99	2.03



Table S4: Simulation results over 1,000 replicates varying stratum size ( $I$ ) and constant treatment effect among switchers ( $\mu$ ), with exactly two switchers per stratum.

I	$\mu$	level	power	$\bar{\tau}_a$	$\bar{\tau}_b$	$\bar{\lambda}$	CI		$100\times$ SD[T( $\lambda$ )]	$100\times$ $S(\lambda)$	$100\times$ SD[T(0)]	$100\times$ $S(0)$
							length	coverage (%)				
100	0.00	0.05	0.05	0.10	0.60	0.00	2.07	94.90	5.61	5.61	5.61	5.61
100	0.25	0.06	0.10	0.10	0.60	0.25	2.05	94.00	5.59	5.58	5.61	5.60
100	0.50	0.06	0.20	0.10	0.60	0.50	2.09	93.70	5.66	5.66	5.69	5.69
100	1.00	0.07	0.57	0.10	0.60	1.00	2.13	93.10	5.90	5.89	5.93	5.91
500	0.00	0.05	0.05	0.10	0.60	0.00	0.80	94.80	2.51	2.52	2.51	2.52
500	0.25	0.05	0.26	0.10	0.60	0.25	0.80	94.90	2.51	2.51	2.52	2.51
500	0.50	0.04	0.68	0.10	0.60	0.50	0.81	95.60	2.53	2.53	2.54	2.54
500	1.00	0.04	1.00	0.10	0.60	1.00	0.84	95.80	2.64	2.64	2.66	2.66
1000	0.00	0.04	0.04	0.10	0.60	0.00	0.56	96.00	1.78	1.78	1.78	1.78
1000	0.25	0.05	0.42	0.10	0.60	0.25	0.55	94.80	1.77	1.77	1.78	1.78
1000	0.50	0.05	0.94	0.10	0.60	0.50	0.56	94.80	1.79	1.79	1.80	1.80
1000	1.00	0.05	1.00	0.10	0.60	1.00	0.58	94.60	1.87	1.87	1.88	1.88

## B.2 Simulation details for always-compliers

### B.2.1 Data-generating process

We generate data for a PoP-NIV design consisting of  $I$  strata. As in the switcher-focused DGP, we vary the following factors:

**Factor 1:** Number of matched strata  $I$ : 100, 500, and 1000.

For each unit  $k$  in matched pair  $j$  within stratum  $i \in [I]$ , its principal stratum membership  $S_{ijk}$  is sampled from a multinomial distribution with the following probabilities:

$$P(S_{ijk} = \text{ACO}) = p;$$

$$P(S_{ijk} \in \{\text{SW}, \text{AT-NT}, \text{AAT}, \text{NT-AT}, \text{ANT}\}) = (1 - p)/5.$$

**Factor 2:** Proportion of always-compliers  $p$ : 0.3, 0.5, and 0.7.

We generate potential outcomes  $(r_{d=0,ijk}, r_{d=1,ijk})$  for each unit as:

$$r_{d=0,ijk} \sim \mathcal{N}(0, 1), \quad r_{d=1,ijk} = r_{d=0,ijk} + \tau_{ijk},$$

where the treatment effect  $\tau_{ijk}$  depends on the unit's principal stratum. Specifically,

- $\tau_{ijk} \sim \mathcal{N}(0.5, 1)$  for switcher strata,
- $\tau_{ijk} \sim \mathcal{N}(0.1, 1)$  for other non-ACO strata (AT-NT, AAT, NT-AT, ANT),
- $\tau_{ijk}$  is drawn from one of the following distributions for always-compliers:

**Factor 3:** Treatment effect among always-compliers,  $\tau_{ijk}^{ACO}$  follows one of the three distributions:

- (i)  $\tau_{ijk}^{ACO} \sim \text{Unif} [\mu - \sqrt{3}, \mu + \sqrt{3}]$ ,
- (ii)  $\tau_{ijk}^{ACO} \sim \mathcal{N}(\mu, 1)$ ,
- (iii)  $\tau_{ijk}^{ACO} \sim \text{Exp}(1/\mu)$ .

Here,  $\mu$  controls the magnitude of the treatment effect among always-compliers, varied as:

**Factor 4:** Effect size among always-compliers  $\mu$ : 0, 0.25, 0.5, and 1.

After generating all potential outcomes, including treatment assignments  $(d_{T^{a_{ijk}}}, d_{C^{a_{ijk}}}, d_{T^{b_{ijk}}}, d_{C^{b_{ijk}}})$  based on  $S_{ijk}$ , we generate the IV assignment vector  $\mathbf{Z}_i$  for each stratum independently, according to the randomization scheme described in Assumption 1. Finally, we determine observed treatment and outcomes:

$$D_{ijk} = d_{C^{a_{ijk}}} \mathbb{I}\{Z_{ijk} = 0_a\} + d_{T^{a_{ijk}}} \mathbb{I}\{Z_{ijk} = 1_a\} + d_{C^{b_{ijk}}} \mathbb{I}\{Z_{ijk} = 0_b\} + d_{T^{b_{ijk}}} \mathbb{I}\{Z_{ijk} = 1_b\},$$

$$R_{ijk} = r_{d=1,ijk} \mathbb{I}\{D_{ijk} = 1\} + r_{d=0,ijk} \mathbb{I}\{D_{ijk} = 0\}.$$

In total, Factors 1–4 define 108 data-generating processes. For each DGP, we generated 1000 datasets and recorded the true sample average treatment effect  $\kappa_{\text{true}}$  among always-compliers in each dataset. We then evaluated the level and power of the randomization-based test from Theorem 1 by testing: (i)  $H_0 : \kappa = \kappa_{\text{true}}$  and (ii)  $H_0 : \kappa = 0$ . Confidence intervals for  $\kappa_{\text{true}}$  were obtained by inverting these tests.

## B.2.2 Simulation results

Table S5: Simulation results over 1000 replicates for varying strata sizes ( $I$ ), proportions of always-compliers ( $p$ ), and mean treatment effects among always-compliers ( $\mu$ ), under a normal distribution of treatment effects among always-compliers:  $\tau_{ijk}^{ACO} \sim \mathcal{N}(\mu, 1)$ .

I	p	$\mu$	level	power	$\bar{l}_a$	$\bar{l}_b$	$\bar{\kappa}$	length	CI coverage (%)
$\tau_{ijk}^{ACO} \sim \mathcal{N}(\mu, 1)$									
100	0.30	0.00	0.04	0.04	0.30	0.44	-0.00	2.94	95.40
100	0.30	0.25	0.05	0.08	0.30	0.44	0.25	2.84	94.60
100	0.30	0.50	0.05	0.15	0.30	0.44	0.50	2.90	94.20
100	0.30	1.00	0.05	0.38	0.30	0.44	1.00	3.06	94.80
100	0.50	0.00	0.05	0.05	0.50	0.60	0.00	1.43	94.60
100	0.50	0.25	0.04	0.12	0.50	0.60	0.25	1.43	96.20
100	0.50	0.50	0.06	0.29	0.50	0.60	0.50	1.45	94.00
100	0.50	1.00	0.05	0.79	0.50	0.60	1.00	1.49	94.90
100	0.70	0.00	0.04	0.04	0.70	0.76	0.00	0.98	95.70
100	0.70	0.25	0.04	0.18	0.70	0.76	0.25	0.98	95.00
100	0.70	0.50	0.05	0.53	0.70	0.76	0.50	0.98	94.60
100	0.70	1.00	0.05	0.98	0.70	0.76	1.00	1.01	95.40
500	0.30	0.00	0.04	0.05	0.30	0.44	0.00	1.05	95.20
500	0.30	0.25	0.05	0.18	0.30	0.44	0.25	1.04	93.70
500	0.30	0.50	0.05	0.48	0.30	0.44	0.50	1.05	94.50
500	0.30	1.00	0.05	0.96	0.30	0.44	1.00	1.10	94.60
500	0.50	0.00	0.04	0.04	0.50	0.60	-0.00	0.61	95.40
500	0.50	0.25	0.03	0.40	0.50	0.60	0.25	0.60	95.60
500	0.50	0.50	0.04	0.88	0.50	0.60	0.50	0.61	94.90
500	0.50	1.00	0.05	1.00	0.50	0.60	1.00	0.63	94.00
500	0.70	0.00	0.04	0.04	0.70	0.76	0.00	0.43	95.30
500	0.70	0.25	0.05	0.62	0.70	0.76	0.25	0.43	94.10
500	0.70	0.50	0.05	1.00	0.70	0.76	0.50	0.43	93.60
500	0.70	1.00	0.05	1.00	0.70	0.76	1.00	0.44	93.40
1000	0.30	0.00	0.05	0.05	0.30	0.44	0.00	0.72	94.30
1000	0.30	0.25	0.05	0.28	0.30	0.44	0.25	0.72	94.00
1000	0.30	0.50	0.05	0.77	0.30	0.44	0.50	0.73	94.90
1000	0.30	1.00	0.05	1.00	0.30	0.44	1.00	0.76	94.30
1000	0.50	0.00	0.05	0.06	0.50	0.60	-0.00	0.42	93.50
1000	0.50	0.25	0.04	0.63	0.50	0.60	0.25	0.42	94.00
1000	0.50	0.50	0.04	0.99	0.50	0.60	0.50	0.42	94.60
1000	0.50	1.00	0.05	1.00	0.50	0.60	1.00	0.44	94.90
1000	0.70	0.00	0.03	0.04	0.70	0.76	0.00	0.30	95.60
1000	0.70	0.25	0.05	0.87	0.70	0.76	0.25	0.30	94.30
1000	0.70	0.50	0.04	1.00	0.70	0.76	0.50	0.30	95.40
1000	0.70	1.00	0.04	1.00	0.70	0.76	1.00	0.31	94.90

Table S6: Simulation results over 1000 replicates for varying strata sizes ( $I$ ), proportions of always-compliers ( $p$ ), and mean treatment effects among always-compliers ( $\mu$ ), under a uniform distribution of treatment effects among always-compliers:  $\tau_{ijk}^{ACO} \sim \text{Unif}[\mu - \sqrt{3}, \mu + \sqrt{3}]$ .

I	p	$\mu$	level	power	$\bar{\tau}_a$	$\bar{\tau}_b$	$\bar{\kappa}$	length	CI coverage (%)
$\tau_{ijk}^{ACO} \sim \text{Unif}[\mu - \sqrt{3}, \mu + \sqrt{3}]$									
100	0.30	0.00	0.06	0.06	0.30	0.44	-0.00	3.00	93.50
100	0.30	0.25	0.05	0.07	0.30	0.44	0.25	2.98	94.10
100	0.30	0.50	0.05	0.13	0.30	0.44	0.50	2.89	94.70
100	0.30	1.00	0.05	0.40	0.30	0.44	1.00	3.07	94.50
100	0.50	0.00	0.05	0.05	0.50	0.60	0.00	1.43	94.70
100	0.50	0.25	0.05	0.12	0.50	0.60	0.25	1.43	94.50
100	0.50	0.50	0.06	0.33	0.50	0.60	0.50	1.44	94.80
100	0.50	1.00	0.04	0.79	0.50	0.60	1.00	1.50	93.90
100	0.70	0.00	0.04	0.05	0.70	0.76	-0.00	0.98	95.10
100	0.70	0.25	0.05	0.15	0.70	0.76	0.25	0.98	94.30
100	0.70	0.50	0.04	0.55	0.70	0.76	0.50	0.98	93.70
100	0.70	1.00	0.05	0.97	0.70	0.76	1.00	1.01	95.00
500	0.30	0.00	0.06	0.05	0.30	0.44	-0.00	1.04	94.50
500	0.30	0.25	0.05	0.15	0.30	0.44	0.25	1.04	94.10
500	0.30	0.50	0.05	0.48	0.30	0.44	0.50	1.06	94.80
500	0.30	1.00	0.06	0.97	0.30	0.44	1.00	1.10	94.40
500	0.50	0.00	0.04	0.04	0.50	0.60	-0.00	0.60	95.20
500	0.50	0.25	0.04	0.37	0.50	0.60	0.25	0.60	94.60
500	0.50	0.50	0.03	0.91	0.50	0.60	0.50	0.61	95.60
500	0.50	1.00	0.05	1.00	0.50	0.60	1.00	0.63	93.20
500	0.70	0.00	0.04	0.06	0.70	0.76	0.00	0.43	94.00
500	0.70	0.25	0.04	0.60	0.70	0.76	0.25	0.43	95.20
500	0.70	0.50	0.05	0.99	0.70	0.76	0.50	0.43	94.00
500	0.70	1.00	0.05	1.00	0.70	0.76	1.00	0.44	93.60
1000	0.30	0.00	0.06	0.06	0.30	0.44	-0.00	0.72	93.90
1000	0.30	0.25	0.04	0.26	0.30	0.44	0.25	0.72	95.10
1000	0.30	0.50	0.05	0.79	0.30	0.44	0.50	0.73	94.30
1000	0.30	1.00	0.06	1.00	0.30	0.44	1.00	0.76	94.10
1000	0.50	0.00	0.05	0.06	0.50	0.60	-0.00	0.42	94.10
1000	0.50	0.25	0.04	0.62	0.50	0.60	0.25	0.42	94.50
1000	0.50	0.50	0.04	0.99	0.50	0.60	0.50	0.42	93.90
1000	0.50	1.00	0.05	1.00	0.50	0.60	1.00	0.44	93.80
1000	0.70	0.00	0.04	0.05	0.70	0.76	0.00	0.30	94.30
1000	0.70	0.25	0.04	0.89	0.70	0.76	0.25	0.30	94.30
1000	0.70	0.50	0.04	1.00	0.70	0.76	0.50	0.30	94.50
1000	0.70	1.00	0.05	1.00	0.70	0.76	1.00	0.31	94.10

Table S7: Simulation results over 1000 replicates for varying strata sizes ( $I$ ), proportions of always-compliers ( $p$ ), and mean treatment effects among always-compliers ( $\mu$ ), under an exponential distribution of treatment effects among always-compliers:  $\tau_{ijk}^{ACO} \sim \text{Exp}(1/\mu)$ .

I	p	$\mu$	level	power	$\bar{\tau}_a$	$\bar{\tau}_b$	$\bar{\kappa}$	length	CI coverage (%)
$\tau_{ijk}^{ACO} \sim \mathbf{Exp}(1/\mu)$									
100	0.30	0.00	0.06	0.06	0.30	0.44	0.00	2.78	94.10
100	0.30	0.25	0.05	0.08	0.30	0.44	0.25	2.84	94.69
100	0.30	0.50	0.06	0.16	0.30	0.44	0.50	2.97	94.10
100	0.30	1.00	0.05	0.40	0.30	0.44	1.00	3.08	94.80
100	0.50	0.00	0.05	0.05	0.50	0.60	0.00	1.31	95.20
100	0.50	0.25	0.05	0.12	0.50	0.60	0.25	1.32	94.80
100	0.50	0.50	0.06	0.34	0.50	0.60	0.50	1.34	94.10
100	0.50	1.00	0.05	0.81	0.50	0.60	1.00	1.48	93.80
100	0.70	0.00	0.04	0.04	0.70	0.76	0.00	0.86	96.00
100	0.70	0.25	0.05	0.20	0.70	0.76	0.25	0.86	95.20
100	0.70	0.50	0.05	0.62	0.70	0.76	0.50	0.89	94.10
100	0.70	1.00	0.05	0.98	0.70	0.76	1.00	1.00	94.20
500	0.30	0.00	0.04	0.04	0.30	0.44	0.00	0.99	96.50
500	0.30	0.25	0.04	0.17	0.30	0.44	0.25	0.99	95.40
500	0.30	0.50	0.05	0.51	0.30	0.44	0.50	1.01	94.80
500	0.30	1.00	0.04	0.97	0.30	0.44	1.00	1.09	94.70
500	0.50	0.00	0.05	0.05	0.50	0.60	0.00	0.55	94.80
500	0.50	0.25	0.05	0.43	0.50	0.60	0.25	0.56	94.30
500	0.50	0.50	0.05	0.93	0.50	0.60	0.50	0.57	95.00
500	0.50	1.00	0.05	1.00	0.50	0.60	1.00	0.63	95.00
500	0.70	0.00	0.06	0.06	0.70	0.76	0.00	0.37	94.20
500	0.70	0.25	0.05	0.74	0.70	0.76	0.25	0.37	94.90
500	0.70	0.50	0.05	1.00	0.70	0.76	0.50	0.39	94.80
500	0.70	1.00	0.05	1.00	0.70	0.76	1.00	0.44	94.40
1000	0.30	0.00	0.04	0.04	0.30	0.44	0.00	0.69	95.80
1000	0.30	0.25	0.05	0.28	0.30	0.44	0.25	0.69	94.00
1000	0.30	0.50	0.05	0.80	0.30	0.44	0.50	0.70	95.20
1000	0.30	1.00	0.04	1.00	0.30	0.44	1.00	0.76	95.80
1000	0.50	0.00	0.04	0.04	0.50	0.60	0.00	0.39	95.50
1000	0.50	0.25	0.06	0.69	0.50	0.60	0.25	0.39	93.80
1000	0.50	0.50	0.05	1.00	0.50	0.60	0.50	0.40	94.10
1000	0.50	1.00	0.04	1.00	0.50	0.60	1.00	0.44	95.30
1000	0.70	0.00	0.04	0.04	0.70	0.76	0.00	0.26	95.70
1000	0.70	0.25	0.06	0.94	0.70	0.76	0.25	0.26	93.40
1000	0.70	0.50	0.04	1.00	0.70	0.76	0.50	0.27	95.50
1000	0.70	1.00	0.05	1.00	0.70	0.76	1.00	0.31	93.50

### B.3 Simulation results for biased randomization inference

$I$	$\Gamma$	Panel A				Panel B	
		$\pi_i \sim \text{Unif}\left[\frac{1}{2}, \frac{\Gamma}{\Gamma+1}\right]$		$\pi_i = \frac{\Gamma}{\Gamma+1}$		$\pi_i = \frac{\Gamma}{\Gamma+1}$	
		Theorem 3	Theorem 2	Theorem 3	Theorem 2	Theorem 3	Theorem 2
100	1.1	0.016	0.048	0.020	0.072	0.021	0.080
100	1.2	0.011	0.043	0.024	0.118	0.027	0.142
100	1.3	0.005	0.104	0.012	0.181	0.033	0.247
100	1.4	0.002	0.106	0.007	0.261	0.024	0.348
100	1.5	0.003	0.107	0.004	0.356	0.028	0.479
100	1.6	0.001	0.148	0.004	0.437	0.038	0.584
100	1.7	0.000	0.159	0.002	0.529	0.032	0.672
100	1.8	0.000	0.185	0.003	0.605	0.023	0.748
100	1.9	0.000	0.206	0.000	0.686	0.030	0.860
100	2.0	0.000	0.257	0.001	0.753	0.030	0.903
500	1.1	0.002	0.065	0.004	0.142	0.025	0.148
500	1.2	0.000	0.129	0.000	0.340	0.022	0.465
500	1.3	0.001	0.214	0.001	0.620	0.020	0.794
500	1.4	0.000	0.316	0.001	0.818	0.029	0.934
500	1.5	0.000	0.419	0.000	0.934	0.026	0.988
500	1.6	0.000	0.523	0.000	0.975	0.022	0.999
500	1.7	0.000	0.647	0.000	0.994	0.032	1.000
500	1.8	0.000	0.677	0.000	0.997	0.020	1.000
500	1.9	0.000	0.761	0.000	0.999	0.025	1.000
500	2.0	0.000	0.827	0.000	1.000	0.030	1.000
1000	1.1	0.001	0.088	0.001	0.224	0.020	0.290
1000	1.2	0.000	0.219	0.000	0.598	0.021	0.751
1000	1.3	0.000	0.343	0.000	0.890	0.021	0.975
1000	1.4	0.000	0.527	0.000	0.971	0.033	0.998
1000	1.5	0.000	0.705	0.000	0.998	0.023	1.000
1000	1.6	0.000	0.808	0.000	1.000	0.020	1.000
1000	1.7	0.000	0.891	0.000	1.000	0.018	1.000
1000	1.8	0.000	0.939	0.000	1.000	0.025	1.000
1000	1.9	0.000	0.977	0.000	1.000	0.019	1.000
1000	2.0	0.000	0.974	0.000	1.000	0.022	1.000

Table S8: Simulation results for the case where IV dose assignments are generated under a partly biased randomization scheme  $\mathcal{M}_\Gamma$ : (I)  $\pi_i \sim \text{Unif}\left[\frac{1}{2}, \frac{\Gamma}{\Gamma+1}\right]$ ; and (II)  $\pi_i = \frac{\Gamma}{\Gamma+1}$ . We report the test level under Theorem 2 and 3 across 1,000 simulations.

## Supplemental Material C: Additional details on the case study

Table S9: Covariate balance before matching. Mean (SD) are reported for continuous variables. Count (percentage) are reported for categorical variables.

	Prior to 1997 ( $G = a$ )		After 1997 ( $G = b$ )		$p$ -value
	Control arm	Treatment arm	Control arm	Treatment arm	
Sample size	4210	4204	4970	4978	
Treatment uptake (=Screening) (%)	0 ( 0.0)	2141 (50.9)	0 ( 0.0)	3989 (80.1)	<0.001
Age (%)					<0.001
$\leq 60$	1031 (24.5)	1049 (25.0)	2930 (59.0)	2915 (58.6)	
(60, 65]	1308 (31.1)	1291 (30.7)	1092 (22.0)	1096 (22.0)	
(65, 70]	1190 (28.3)	1188 (28.3)	650 (13.1)	663 (13.3)	
$> 70$	681 (16.2)	676 (16.1)	298 ( 6.0)	304 ( 6.1)	
Age	64.75 (5.09)	64.69 (5.08)	60.40 (5.26)	60.42 (5.31)	<0.001
Sex (=Male) (%)	1568 (37.2)	1566 (37.3)	2160 (43.5)	2180 (43.8)	<0.001
Race (=Minority) (%)	864 (20.5)	915 (21.8)	704 (14.2)	700 (14.1)	<0.001
Education (%)					<0.001
No high school	585 (13.9)	616 (14.7)	351 ( 7.1)	369 ( 7.4)	
High school	1775 (42.2)	1639 (39.0)	1586 (31.9)	1589 (31.9)	
College or above	1850 (43.9)	1949 (46.4)	3033 (61.0)	3020 (60.7)	
Smoking status (%)					0.663
Non-smoker	1803 (42.8)	1798 (42.8)	2101 (42.3)	2076 (41.7)	
Current smoker	562 (13.3)	573 (13.6)	700 (14.1)	729 (14.6)	
Former smoker	1845 (43.8)	1833 (43.6)	2169 (43.6)	2173 (43.7)	
BMI ( $> 25$ ) (%)	2771 (65.8)	2758 (65.6)	3532 (71.1)	3492 (70.1)	<0.001
Colorectal cancer (=Confirmed cancer) (%)	82 ( 1.9)	65 ( 1.5)	65 ( 1.3)	58 ( 1.2)	0.012